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1 Summary 
Ewing sarcoma (ES) is the second most frequent bone cancer in childhood. Clinically, ES 
appears as very aggressive osteolytic tumor with early tendency for development of metastasis. It 
belongs to the group of small-round-blue-cell tumors and is comprised of largely undifferentiated 
cells. The unique feature of this tumor is presence of the balanced t(11;22)(q24;q12) translocation 
in more than 85% of cases. This gene rearrangement results in the expression of a chimeric fusion 
protein where RNA binding domain of EWS is exchanged by the DNA binding domain of the ets 
transcription factor FLI1, thus generating a dysregulated transcription factor EWS/FLI1. More 
than 18 less represented alternative translocations involving EWS and other ets protein family 
members have been described since. 
Extensive evidence supports the fact that EWS/FLI1 is an essential oncogenic component of ES 
development.  Its oncogenic activity is thought to be mediated through inappropriate regulation 
of target genes that are crucial for the fully malignant phenotype. Apart from having transforming 
and tumorigenic potential, even more important is that EWS/FLI1 appears to be necessary for 
tumor cell maintenance. For these reasons EWS/FLI1 represents an attractive target. However, it 
is widely accepted that transcription factors are ‘’undruggable’’, and EWS/FLI1 as intrinsically 
disordered protein is not prone to direct inhibition by a small molecule in the classical sense. 
No targeted agents have been routinely introduced into therapy of ES. Even though in the last few 
decades there has been considerable progress in both diagnosis as well as treatment of the 
localised disease, only 15% of patients with metastatic disease survive. Current treatment 
regimens of ES are not fully exploiting the fact that specific inhibition of signalling pathways is 
now possible. More specifically, it is not known whether specific pathway could affect the 
activity of EWS/FLI1.  
In this thesis, we characterized PHLDA1 as a novel direct target gene whose expression is 
repressed by EWS/FLI1. Moreover, the role of PHLDA1 in ES was addressed in this study. 
Using this gene and additional specific well-characterized target genes such as NROB1, NKX2.2, 
and CAV1, all activated by EWS/FLI1, as a read-out system, we established a screening system 
that is capable of detecting compounds targeting activity and/or expression of EWS/FLI1 either 
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directly or indirectly. This system is an important simplification of the previously applied gene 
expression based high-throughput screening, represents a more targeted approach than screenings 
based on survival or proliferation only, and is more robust than a screening approach based on a 
single-gene reporter assay. We screened a small-molecule compound library enriched for FDA-
approved drugs for substances that modulated the expression of EWS/FLI1 target genes. Among 
a hit-list of 9 well known drugs such as camptothecin, fenretinide, etoposide and doxorubicin, we 
also identified the kinase inhibitor midostaurin (PKC412). Subsequent experiments demonstrated 
that midostaurin is able to induce apoptosis in a panel of 6 ES cell lines in vitro and can 
significantly suppress xenograft tumor growth in vivo. These results suggest that midostaurin 
might be a novel drug that is active against ES cells which might act by modulating the 
expression of EWS/FLI1 target genes. 
In the second part of this thesis, in order to identify molecular pathway(s) that may contribute to 
the transcriptional activity and oncogenic properties of EWS/FLI1, we used our well established 
screening approach and performed screening of a small library of 153 targeted inhibitors covering 
all major signaling pathways. We discovered PI3K inhibitors as potent modulators of EWS/FLI1 
expression. This finding was confirmed in several ES cell lines and off target effects of the PI3K 
inhibitors was excluded by performing genetic loss of function experiments. Analysis of the 
EWS/FLI1 promoter region using various deletion constructs in reporter gene assays determined 
two 12bp minimal elements where transcription factor(s) under PI3K control is binding. 
Elucidating the direct link between PI3K and EWS/FLI1 is of importance, and identity of the 
responsible transcription factor(s) might provide novel therapeutic opportunities. 
Results presented in this thesis clearly demonstrate that screening approach here established can 
be used for both screening for compounds effective against ES as well as for screening targeted 
inhibitors leading to better understanding of the biology of ES. Together it should lead to 
development of novel therapeutic approaches for the treatment of ES. 
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2  Zusammenfassung 
Ewing Sarkoma (ES) ist die zweithäufigste Ursache für Knochenkrebs bei Kindern. Klinisch 
gesehen ist es ein sehr aggressiver osteolytischer Tumor mit einer Tendenz zur frühen 
Metastasierung. ES gehört zur Gruppe der kleinen, runden blauzelligen Tumore bestehend aus 
undifferenzierten Zellen. Die Besonderheit dieses Tumors liegt in der balancierten Translokation 
t(11;22)(q24;q12), die in mehr als 85% aller Fälle auftritt. Diese Genumlagerung führt zur 
Expression eines chimären Fusionsproteins wobei die RNA-Bindungsdomäne des EWS mit der 
DNA-Bindungstelle des ets-Transkriptionsfaktors FLI1 ausgetauscht ist. Dadurch entsteht der 
deregulierte Transkriptionsfaktor EWS/FLI1. Es gibt mehr als 18 alternative, jedoch 
unterrepräsentierte, Translokationen, die ebenfalls EWS oder andere ets-Familienmitglieder 
enthalten. 
Es gibt eindeutige Hinweise dafür, dass EWS/FLI1 ein essentieller onkogener Bestandteil für die 
Entwicklung von ES ist. Die onkogene Aktivität besteht vor allem aus der Deregulierung von 
Zielgenen, die wichtig sind für die vollständige Ausprägung eines malignen Phänotyps. Neben 
diesen transformierenden und tumorigenen Eigenschaften scheint EWS/FLI1 eine noch 
wichtigere Rolle im Überleben der Tumorzellen zu spielen. Daher repräsentiert das EWS/FLI1 
Protein ein attraktives therapeutisches Zielmolekül. Allerdings ist weithin akzeptiert, dass 
Transkriptionsfaktoren per se nicht medikamentös behandelbar sind. EWS/FLI1, ein intrinsisch 
ungeordnetes Protein, kann daher nicht im klassischen Sinne direkt inhibiert werden, wie etwa 
mit sogenannten „kleinen Molekülen“. 
Es werden keine zielgerichteten Mittel routinemässig in der ES Therapie verwendet. Erst in den 
letzten Jahrzehnten gab es erste Fortschritte in der Diagnose und Behandlung von lokalisierten 
Tumoren, nur 15% der Patienten mit Metastasen überleben. Die aktuellen 
Behandlungsmöglichkeiten von ES schliessen noch nicht das Wissen ein, dass man spezifische 
Signalwege inhibieren kann. Genauer gesagt ist es noch nicht bekannt, ob bestimmte Signalwege 
die Aktivität von EWS/FLI1 beeinflussen. 
In dieser Doktorarbeit charakterisierten wir PHLDA1 als ein neues direktes Zielgen, dessen 
Expression von EWS/FLI1 unterdrückt wird und charakterisieren dessen Rolle in ES. Dieses Gen 
und weitere spezifische, gut charakterisierte Zielgene wie NROB1, NKX2.2, and CAV1, die alle 
durch EWS/FLI1 aktiviert werden, nutzten wir als Komponenten für ein Screening-System, mit 
dem wir molekulare Verbindungen detektieren können, die die Aktivität oder Expression von 
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EWS/FLI1 direkt oder indirekt verändern. Dieses System ist eine wichtige Vereinfachung von 
früheren auf Genexpression basierenden Hochdurchsatz-Screenings. Es repräsentiert einen 
zielgerichteteren Ansatz als ein Screening, das nur auf der Überlebens- und Proliferationsrate 
beruht, und ist mehr robust als ein Screening das auf Einzelgen-Reporter-Untersuchungen beruht. 
Wir haben eine Bibliothek von so genannten „kleinen Molekülen“ mit vor allem FDA 
anerkannten Medikamenten überprüft auf Substanzen, welche die Expression von EWS/FLI1 
Zielgenen verändern. Unter der Topliste von 9 gut bekannten Medikamenten, wie Camptothecin, 
Fenretinide, Etoposide und Doxorubicin, hatten wir auch den Kinaseinhibitor Midostaurin 
(PKC412) identifiziert. Weiterfolgende Experimente zeigten, dass Midostaurin in vitro Apoptose 
in 6 ES Zelllinien induzieren und in vivo das Tumorwachstum in Xenografts signifikant 
unterdrücken kann. Diese Resultate zeigen, dass Midostaurin ein neues Medikament werden 
könnte, das aktiv ist gegen Ewing Zellen und wahrscheinlich die Expression von EWS/FLI1 
Zielgenen verändert. 
Im zweiten Teil dieser Arbeit nutzten wir unseren etablierten Screening Ansatz um neue 
molekulare Signalwege zu identifizieren, die zur transkriptionalen Aktivität und den onkogenen 
Eigenschaften von EWS/FLI1 beisteuern, und führten ein Screening mit einer kleinen Bibliothek 
von 153 zielgerichtet Inhibitoren durch, die alle wichtigen Signalwege abdeckt. 
Wir entdeckten PI3K Inhibitoren als potentielle Regulatoren der EWS/FLI1 Expression. Diese 
Erkenntnis wurde in mehreren ES Zelllinien bestätigt und „off target“ Effekte des PI3K Inhibitors 
wurden durch genetische „loss-of-function“ Experimente ausgeschlossen. Die Analyse der 
EWS/FLI1 Promoterregion durch verschiedene Deletionskonstrukte in Reportergenversuchen 
ermittelte zwei 12bp minimale Elemente an der Transkriptionsfaktoren unter PI3K Kontrolle 
binden können. 
Die Aufklärung dieser direkten Verbindung von PI3K und EWS/FLI1 ist sehr wichtig, da diese 
neue mögliche therapeutische Möglichkeiten darstellen. 
Die hier präsentierten Resultate zeigen klar, dass das etablierte Screening System für eine 
Untersuchung von Verbindungen oder zielgerichteten Inhibitoren, die effektiv gegen ES sind, 
genutzt werden kann, was zu einem besseren Verständnis der ES Grundlagen führen kann. 
Zusammen sollte es zu neuen Möglichkeiten von therapeutischen Ansätzen in der Behandlung 
von ES führen. 
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3 Abbreviations 
 
  
AAPC average annual percentage change 
ACCIS automated childhood cancer information system 
ARA-C cytosine arabinoside 
CAV1 caveolin 1 
CCND1 cyclin D1 
ChIP chromatin immunoprecipitation 
CREB1 cAMP responsive element binding protein 1 
CT computed tomography 
DMSO dimethyl sulfoxide 
DNA-BD DNA binding domain 
EGFR epidermal growth factor receptor 
ERK extracellular signaling-regulated kinase 
ES Ewing sarcoma 
ES/PNET Ewing sarcoma/primitive neuroectodermal tumor 
ETS  E twenty six 
EWSR1 Ewing sarcoma breakpoint region 1  
FLI1 Friend leukemia virus integration 1 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
IGF1 insulin-like growth factor 1 
IGF1R insulin-like growth factor 1 receptor  
IGFBP3 insulin-like growth factor binding protein 3 
IHC immunohistochemistry 
MAPK mitogen-activated protein kinase 
MRI magnetic resonance imaging 
mRNA messenger RNA 
MSC mesenchymal stem cell 
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mTOR mammalian target of rapamycin 
NFκB nuclear factor kappa b 
NKX2.2 NK2 homeobox 2 
NROB1 nuclear receptor subfamily 0, group B, member 1 
PARP poly ADP ribose polymerase 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
PDGFRB platelet-derived growth factor receptor beta 
PHLDA1 pleckstrin homology-like domain, family A, member 1 
PI3K phosphatidylinositol-4,5-bisphosphate 3-kinase 
qPCR quantitative polymerase chain reaction 
RRM RNA recognition motif 
RTK receptor tyrosine kinase 
shRNA short hairpin RNA 
siRNA small interfering RNA 
SPRY2 sprouty homologue 2 
TMA tissue microarray 
TUNEL deoxynucleotidyl transferase doxyuridine triphosphate nick end labeling 
VACD vincristine, actinomycin D, cyclophosphamide, doxorubicin 
VAIA vincristine, actinomycin D, ifosfamide, doxorubicin 
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4.1 Pediatric cancers 
Immediately after accident injuries, cancer is the leading cause of death in children in developed 
countries
1
. Considering that childhood cancers represent only 2% of all cancers they are rare 
neoplasms
2
. The incidence rate of cancer among children under 15 years of age is about 140 per 
million. Despite improvements in the diagnostics and treatment of pediatric cancers that led to 
considerable increase in survival rates in the past several decades, the fact that these cancers are 
so rare still represents the major obstacle for in depth-understanding of their etiology, risk factors 
and biological mechanisms.  
4.1.1 Epidemiology 
 As shown in Figure 1, there are large variations in the incidence of tumor entities among 
different age groups. In infants, the single most frequent neoplasm is neuroblastoma with close to 
one-third of all cases, while neuroblastomas, retinoblastomas, and nephroblastomas together 
account for about half of all malignancies. Among the 1–4-year-olds leukemias are predominant 
(44.9%). In age groups 5–9 and10–14 years, leukemias, lymphomas and CNS tumors represent 
over three quarter of all malignancies. At the same time in these age groups embryonal tumors 
are practically non-existent, while bone tumors are observed only then in any relevant numbers. 
Leukemias and CNS tumors are markedly less frequent in adolescents (15-19 years) than in the 
younger age groups. The number of carcinomas and germ cell tumors is considerably larger in 
adolescents (32.4%) than among the 10–14-year-olds (8.1%).  
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Figure 1 Relative frequencies for the main ICCC-3 diagnostic groups by age groups: (a) age <1 year; (b) age 1–4 
years; (c) age 5–9 years; (d) age 10–14 years; (e) age 15–19 years (adapted from3) 
If we consider sex distribution of pediatric cancers, as shown in Figure 2 boys of any age have a 
higher risk of cancer than girls, with an overall sex ratio 1.2. 
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It is noteworthy that in the first five years of life, malignancies are about twice as frequent as 
among 5–14 year olds. 
 
Figure 2 Age- and sex-specific incidence rates per million children for childhood cancer (age 0–14) (adapted from3) 
4.1.2 Geographical and temporal trends of incidence rates 
Even though there are some geographical differences in the incidence rates, the incidence 
reported by 24 major cancer registries varies between 120 and 170 cases per million. However, 
what is of bigger concern is that increasing incidence rates were reported by a number of 
developed countries such as Great Britain
4
, Scandinavian countries
5
 and USA
6
. In Europe, an 
overall average annual percentage change (AAPC) of 1.1% was observed. AAPC values vary 
from 1.0% in the North to 1.4% in the East and from 0.9% for males to 1.4% for females. 
Considering the age groups, the biggest increase is seen in children younger than one year of age 
(AAPC: 2.1%). Out of twelve main diagnostic groups eight show a significant increase with 
AAPC ranging from 0.6% in leukemias to 1.8% in soft-tissue sarcomas. 
4.1.3 Survival rates 
Over the last few decades the survival rates for childhood cancer have improved considerably in 
the developed countries.  The improvement in survival from the 1970s to the 1990s in the 
Western and Eastern Europe (East: former socialist economy countries plus Turkey without the 
former German Democratic Republic) is shown in Figure 3. In both Western as well as Eastern 
countries there was significant increase in the survival, but this improvement is less pronounced 
in Eastern Europe and survival rates are somewhat below the rates observed in Western Europe 
7
. 
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Figure 3 Survival rates by decade of diagnosis for childhood cancer (age 0–14) for East and West Europe (adapted 
from
3
) 
According to the EUROCARE data the relative risk of death was 8% lower in the 2000–2002 
time period than in the years 1995–1999. In general, rates varied between 78% and 83% in the 
majority of countries
8
. Different data base, ACCIS (1988–1997), shows rates ranging from 62% 
to 77% in five European regions
9
.  
4.1.4 Treatment 
Upon establishing a proper diagnosis, a specific therapy is assigned to each specific tumor type. 
This is usually a multimodal approach that includes surgical resection (in solid tumors), 
chemotherapy and/or radiation. The exact treatment depends not only on the tumor type but also 
the localization of the primary tumor as well as presence of metastases. 
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Tumor type Side effect
leukemia, 
sarcomas
 haematuria, bladder cancer, marrow damage, 
leukemia, gonadal failure, fibrosis, Fanconi 
syndrome
sarcomas organ dysfunction
lymphoma
lymphomas, 
leukemia, 
neuroblastoma, 
leukemia, 
sarcomas
leukemia, 
sarcomas, 
neuroblastoma
Table 1. Common agents used in pediatric cancer treatment and their common 
late side effects
Heart damage, vomiting, secondary neoplasms
Antimetabolites          
ARA-C (HD) 
Methotrexan (HD)               
6-mercaptopurine                  
6-thioguanine
 Neurological dysfunction, Intellectual 
retardation, liver dysfunction,  liver 
dysfunction
Miscellaneous 
Prednisone 
Dexamethasone        
Vinca alkaloids 
Procarbazine      
Cisplatin           
Etoposide
osteoporosis                                                            
gonadal failure                                                           
low magnesium, hearing loose, decrease 
glomerular filtration rate,                                                            
secondary neoplasms
HD, high doses
Agent 
Alkylating agents 
Ifosfamid 
Antibiotics 
Actinomycin D 
Bleomycin
Anthracyclines  
Daunorubicin  
Doxorubicin
 
Cytotoxic chemotherapy is routinely used and it exploits the fact that tumor cells are fast dividing 
cells and hence can be distinguished from the majority of normal cells in the body. Therefore, 
these agents are most often targeting DNA causing impairment of either DNA replication or 
DNA repair and thus eliminate fast dividing cells. Other drugs, like actinomycin D target 
microtubuli also leading to death of fast dividing cells. Despite the enormous improvement in 
survival since the use of these agents, there are several problems related to this approach. First, 
this is a rather unspecific treatment and thus has effect on other, normal dividing cells of the 
body. As a consequence serious side effects including organ dysfunctions, secondary 
malignancies, and impairment of growth and development can be observed (Table 1). Given the 
fact that the patients are children, the well-being of long term survivors is essential. For this 
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reason there is a need for more targeted therapy approaches. Additional reason that urges the 
establishment of targeted therapy is the fact that the current treatment options seem to have 
reached a plateau of success and further intensification of the chemotherapy does not lead to 
increase in survival rates. 
Targeted therapy approach is supposed to use the molecular differences between tumor cells and 
normal cells in order to specifically target just the tumor cell and spare the normal cell. There are 
two main approaches: 
 Approach based on certain differences in the presence of molecular markers between 
normal and cancer cell. These cancer specific markers can then be targeted by antibodies 
or antibody like molecules linked to cytotoxic agents. Also, it is possible to boost immune 
response against cancer specific markers. 
 Approach based on exploiting the differences in the dependency on some functional 
characteristics between normal and cancer cell. According to Benson et al. we can 
distinguish four dependencies
10
: 
Genetic dependence refers to phenomenon also known as oncogene addiction meaning that many 
cancer cells are only dependent on some of the abnormalities.  
Synergy dependence refers to situation in some cancer cells where mutation of one   pathway 
renders these cells dependent on another pathway. 
Lineage dependence refers to observation that cancer cells are often dependent on the same 
signaling pathways as their normal counterparts. 
Host dependence refers to situation where either single tumor cells or the whole tumor can 
depend on activities coming from the host environment such as angiogenesis or growth factors 
produced by stromal cells. 
All of the above dependencies provided possibilities for targeting that have already been 
successfully used to inhibit proliferation or to induce apoptosis in tumor cells while at the same 
time normal cell remain less affected. Therefore, it is quintessential to discover dependencies for 
each tumor type and thus open up a way for targeted approaches. Use of gene expression or 
mutational analysis as well as high throughput sequencing and other techniques has led to the 
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identification of novel molecular markers that can potentially be used for targeted therapy. 
Extensive pre-clinical validation of molecular targets will surely lead to establishment of new 
clinical targeted therapeutic approaches for many cancer types.  
4.2 Ewing sarcoma  
4.2.1 Epidemiology 
Ewing sarcoma (ES) is the second most frequent bone tumor in children and adolescents. It got 
its name from the man who first described it, pathologist James Ewing. He believed that this 
tumor develops from blood vessels of the bone and hence he described it as diffuse endothelioma 
of the bone or later as endothelial myeloma. Today, the World Health Organization classification 
uses Ewing sarcoma/Primitive Neuroectodermal Tumor (ES/PNET)
11-13
. This term comprises 
several entities formerly known as classical ES, Askin’s tumor ES of the chest wall and 
peripheral neuroectodermal tumor for ES with neuronal differentiation. This highly aggressive 
cancer affects bone and in one quarter of cases soft tissues mostly in childhood. Incidence is 1-3 
per million per year which makes it a rare cancer. It has a slight male predominance and is much 
more frequent in Caucasians, whereas it is rarely observed in Africans
13-15
. The peak of incidence 
is at the age of 15 but ES continues to be diagnosed through the third decade of life. Interestingly, 
with the advances in molecular diagnosis of undifferentiated sarcomas, the reported incidence of 
ES in young adults is increasing
16-18
. Even though ES can affect any bone of the body it most 
commonly affect pelvis and the long bones. 
4.2.2 Clinical presentation 
Most often patients with ES present pain as the first tumor related symptom. This pain is in 
physically active patients frequently associated with athletic trauma and 10% of these patients are 
presenting pathologic fracture as initial symptom
19
. Further physical examination reveals 
palpable mass with pathologic findings in the vast majority of cases. However, in approximately 
30% of the patients there are systemic symptoms such as weight loss or fever and these are often 
correlating with advanced stage of the disease. Reports indicate the duration of the symptoms 
prior to the diagnosis to be most often between 4 and 6 months
20-21
. Since ES affects bone and 
soft tissue, we can distinguish skeletal and extra-skeletal tumors. Approximately 80% of all ES 
cases are diagnosed in the first two decades of life, with 80% of these cases being skeletal ES that 
most commonly affects the axial skeleton (50%), with 25% of tumors occurring in the pelvis 
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alone
22
. In 46% of cases it arises from the diaphysis of the long bones, from these approximately 
20% in femur. In primarily adult cases more than half are extraskeletal mainly affecting kidneys 
and uterus
13, 15, 17
. These patients usually present with vague abdominal pain. Approximately 30% 
of all ES patients present with detectable metastasis at diagnosis. In 35% metastasis are restricted 
to the lung, followed by isolated bone/bone marrow involvement, combined lung plus bone/bone 
marrow metastases, and only very rarely other sites. Metastases in the local lymph nodes are 
uncommon and in most cases are associated with disseminated disease
11, 17
. 
4.2.3 Diagnosis, imaging and staging 
If there is a suspected tumor the first step in the assessment phase is imaging (Figure 4). In the 
case of assumed osseous lesions, initial imaging is a radiograph in 2 plains. Radiographic signs of 
ES are tumor osteolysis accompanied by periosteal reaction such as onion skin pattern, calcified 
spiculae or Codman triangle
23
. The exact extent of the local tumor must be determined by 
computed tomography (CT) or magnetic resonance imaging (MRI). Even though in assessing the 
osseous lesion CT is superior to MRI, MRI can more accurately define the intra medullary and 
soft tissue extent of ES as well as anatomic relations to adjacent vessel/nerve bundles, which is 
crucial in planning biopsy and local therapy. All local imaging techniques should display the full 
compartment including adjacent joints to assess skip metastases. In order to avoid hemorrhage 
and edema artefacts, local imaging must be completed before biopsy
24
. Nevertheless, the 
definitive diagnosis of malignant bone tumors requires biopsy proof. To achieve this core or fine-
needle biopsy needs to be performed. ES often has extensive necrosis and therefore it is 
necessary to make sure that sufficient material is harvested for diagnosis, including subsequent 
immunohistochemical and molecular analyses. Hence, usually several cores are necessary, with 
frozen sections verifying representative sampling. Despite the fact that these methods are 
intended to expedite diagnosis, uncertain results even in experienced centers may actually delay 
diagnosis
25
. Therefore, an open biopsy is still considered the standard approach in many 
specialized sarcoma centers. Biopsies need to be carefully planned following clinical examination 
and complete local imaging, since any biopsy tract is considered contaminated and should be 
marked indelibly (e.g., with a tattoo or incision) so that it can be excised in definitive tumor 
resection and/or included into the radiation field of definitive radiation. That is exactly why 
biopsy should be done by the same multidisciplinary oncology team responsible for final local 
treatment. 
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Figure 4 ES diagnostic imaging and histology. (A) Conventional radiograph in 2 planes of right fibula ES. (B) 
Corresponding MRI (T1-weighted image with gadolinium contrast). (C) PET-CT of advanced ES with pulmonary 
metastases. Left panels, chest CT; right panel, whole-body FDG-PET; middle panels, fusion images with FDG tracer 
uptake by viable metabolically active tumor fractions, color-coded (adapted from
26
) 
Upon pathological diagnosis of ES, further staging is focused on assessment of metastases, which 
are detected in approximately 25% of patients. The usual staging procedures are chest CT scan, 
99m-technetium whole-body bone scintigraphy, and bone marrow aspirate and biopsy. Even 
today bone scintigraphy remains an indispensible standard for the detection of bone metastases. 
Recently it is supplemented with metabolic[18F] fluoride oxyglucose positron emission 
tomography (FDG-PET), increasingly performed as fusion PET-CT together with a diagnostic 
chest CT scan
27
. First prospective studies show superiority of FDG-PET in assessing bone/bone 
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marrow and soft tissue involvement compared with conventional staging, whereas PET-CT or CT 
is more reliable than FDG-PET in depicting lungmetastases
28-31
. With this improvement it is 
possible to expect that FDG-PET findings may lead to changing the stage and consequently the 
treatment group in some patients. Every one of these techniques has its limitations in terms of 
sensitivity and specificity. With improvements these techniques are evolving so it is necessary to 
establish clear criteria for clinical trials. However, even though the sensitivity of diagnostic 
imaging has been improved in the last decades, the fraction of patients with detectable metastases 
at diagnosis has remained constant at 20–25% 
4.2.4 Histology 
Morphologically ES cells are characterized by a high nuclear to cytoplasm ratio and they exhibit 
faintly eosinophilic cytoplasm containing glycogen appearing granules that stain positive for 
periodic acid–Schiff (PAS). Mitotic activity is low, cytoplasmic borders are indistinct and nuclei 
are round with evenly distributed chromatin 
32
. Most tumors express surface antigen CD99 as 
well as vimentin. 
A                                                                                                     B 
 
Figure 5 ES histology (A) H&E staining, Left panel, 20x magnification; right panel, 40x magnification. (B) ES bone 
marrow metastasis (smear from bone marrow aspirate) (adapted from
26
) 
ES, together with neuroblastoma, alveolar rhabdomyosarcoma and lymphoblastic lymphoma 
belongs to a group of small blue round cell tumors that exhibit poorly differentiated cell 
phenotype (Figure 5). Since histology and in part immunophenotype of ES overlaps with these 
other small round blue cell tumors, a complex immunohistochemical approach with analysis of 
multiple markers is necessary in order to establish the correct diagnosis. ES shares expression of 
CD99 with lymphoblastic lymphomas, but the difference comes from the expression of CD45 in 
lymphoblastic lymphomas that is absent in ES. Alveolar rhabdomyosarcoma might also express 
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CD99 but it expresses desmin, myogenin and MyoD1 that are not expressed in ES. Expression of 
neural specific enolase (NSE) and S-100 is common to both neuroblastomas as well as ES. 
However, neuroblastomas are vimentin-negative and neurofilament-positive whereas Ewing 
sarcomas are not
33
. Poorly differentiated small synovial sarcoma might express CD99 but lacks 
other histological markers which makes it difficult to set histology based differential diagnosis.  
If the tumor shows neuroectodermal features it is considered as PNET. 
All these similarities in the expression of antigen markers along with poorly differentiated 
morphology of this family of tumors made the diagnostic very difficult. However, ES like some 
other sarcomas has specific chromosomal rearrangements that can be used as biomarkers. 
Discovery of these genetic events provided unambiguous diagnosis based on molecular 
techniques like fluorescence in situ hybridization or polymerase chain reaction. 
4.2.5 Prognostic factors 
The single most important prognostic factor is the stage of the disease which basically comes 
down to one question, presence or absence of metastases at diagnosis. Also, there is different 
prognostic relevance depending on the site of metastases. Thus, patients with pulmonary 
metastases have better prognosis than those with bone metastases
16, 34-35
.  In addition, detection of 
tumor cells in the bone marrow by detecting fusion transcripts using RT-PCR may have 
prognostic value
36-37
. 
Apart from metastases, the main prognostic factors in ES are tumor volume and the site of the 
primary tumor, chemotherapy response and the age of the patient
16-17, 34-35
. Tumor necrosis 
induced by chemotherapy has been shown in several studies to be the most important indicator of 
event free survival in ES patients with surgical treatment after induction chemotherapy
17, 38-39
. 
Among cytogenetic aberrations with prognostic significance, gain of 1q and loss of 16q are 
reported to have inverse correlation to outcome
40-41
. Also, presence of mutations/alterations in 
p53 and p16 are correlated with worse prognosis
42
.   
    23 
 
4.3 Biology of Ewing sarcoma 
4.3.1 Chimeric fusion protein 
ES represents morphologically heterogeneous tumors but they all have one common feature 
which is nonrandom chromosomal translocation involving the EWS gene and one of the members 
of the ETS family of transcription factors
43
. Approximately 85% of ES tumors have the 
t(11;22)(q24;q12) chromosomal abnormality
44
. This translocation leads to in frame fusion of the 
EWSR1 (also known as EWS) gene on chromosome 22 to the FLI1gene on chromosome 11 and 
encodes the EWS/FLI1 fusion protein
45
 (Figure 6). EWS/FLI1 contains the amino-terminus of 
EWS fused, in frame, to the carboxyl-terminus of FLI1transcription factor
46
. In ES cases lacking 
EWS/FLI1, there are alternative translocations present that fuse EWS to other ETS family 
transcription factors, like ERG (5% of cases), ETV1, ETV4, FEV and others
47-52
, which all most 
likely mimic EWS/FLI1
52-55
. Moreover, the presence of the fusion enabled easy differential 
diagnosis by performing PCR and thus distinguishing ES from other histo/morphologically 
similar tumors such as neuroblastomas, rhabdomyosarcomas and giant cell tumors
56
. 
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Figure 6 (A) Domain structures of wild-type EWS, wild-type FLI and the EWS/FLI fusion proteins. SYGQ: serine 
tyrosine-glycine glutamine rich transactivation region; RGG: arginine-glycineglycine rich regions; RRM: RNA 
recognition motif; Zn: putative zinc finger; PTD: pointed domain; DNA-BD: DNA binding domain; Pro: proline-rich 
activation domain. Arrows indicate breakpoints in wild-type EWS and FLI included in commonly observed subtypes 
of the EWS/FLI fusion protein. (B) Genomic structures of the EWSR1 and FLI1 genes. Breakpoints in the EWSR1 
and FLI1 genes occur in many introns. Following splicing, the exons join together to generate various subtypes of 
EWS/FLI. Some of the previously described EWS/FLI fusion subtypes are depicted here. (adapted from
57
) 
Apart from encoding for EWS/FLI1 fusion protein, the chromosomal rearrangement 
t(11;22)(q24;q12) has two additional consequences. First, due to this translocation EWS/FLI1 is 
under the control of EWSR1 promoter and hence it is constitutively expressed in tumor cells. 
Secondly, there is haploinsufficiency for these two genes. When it comes to FLI1 copy it 
probably has no major consequence since FLI1 is only expressed at very low levels in ES cells. 
However, the consequence of disrupting one copy of EWSR1 is not understood at the time. 
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4.3.2 Different EWS/FLI1 fusion types 
As a result of different genomic breakpoints usage in the EWSR1 and FLI1 genes there will be 
generation of different, highly related isoforms of EWS/FLI1. All breakpoints occur within 
introns of these two genes and the final fusion is also within introns
58-60
. Upon splicing of the 
transcribed RNA, the mRNA incorporates 5’ exons from EWSR1 fused to 3’ exons derived from 
FLI1
45, 58-59
. These splicing variants are named according to the frequency of a certain fusion 
type. The most frequent so called type I fusion is a fusion between exon 7 of EWSR1 and exon 5 
of FLI1
45
. For the first 4 most frequent rearrangements the same nomenclature applies, thus they 
are referred to as Type I, Type II, Type III and Type IV. For the other much less frequent fusion 
subtypes there is no strict nomenclature. The influence of these minor differences has been 
extensively investigated as a prognostic factor. It was at first suggested that it has a prognostic 
value
61
. Some earlier studies implied that patients with Type I fusion have better relapse free 
survival but recent reevaluation of this claim has been done in a large cohort of patients. In this 
study it has been excluded that fusion type has any impact on disease progression or survival
37, 62
. 
4.3.3 The EWS Protein 
The EWS protein is a member of TET family which also includes liposarcoma fusion protein 
TLS/FUS and the human TATA binding protein-associated factor (hTAFII68)
63-64
. These are 
RNA-binding proteins containing a transcriptional activation domain(s) in the N-terminus and an 
RNA recognition motif in their C-terminus
65-66
. Since they lack a secondary structure this 
suggests a probable involvement as cofactor. However, structure of TET proteins doesn’t imply 
that they function as classical transcription factors or co-factors, given the fact that they contain 
RNA recognition motifs and have been shown to bind RNA as well as both single-stranded and 
double-stranded DNA
64, 66-68
. Interestingly, expression of TET proteins is associated with a 
number of solid tumors such as myxoid chondrosarcoma (EWSR1-NR4A3, TAF15-NR4A3, 
TCF12-NR4A3, TFG-NR4A3), angiomatoid fibrous histiocytoma (FUS-ATF1, EWSR1-ATF1, 
EWSR1-CREB1) where their N-terminal part is being involved in chromosomal translocations 
with various transcription factors
69
.  The EWS protein is expressed in all tissues and can be 
considered housekeeping gene. It’s mainly located in the nucleus, even though it is present in 
smaller amounts at the cell membrane and the cytoplasm
70-71
. It is expressed ubiquitously with 
similar levels throughout the cell cycle. The transcriptional potency of the N-terminal domain of 
EWS that is observed in different tumorigenic fusion proteins suggests that it may play a role as a 
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transcription factor. Also, it has been shown to play a role in splicing, in RNA processing, 
translation inhibition and in cytoskeleton stabilization
72-76
. 
4.3.4 The Fli1 Protein 
This ETS transcription family consists of approximately 30 genes divided in distinct subfamilies. 
Among others they include FLI1, ERG, ETV1, E1AF, FEV and ZSG. In cooperation with other 
transcription factors and cofactors the ETS transcription factor family of proteins is involved in a 
variety of mammalian developmental processes at the cellular, tissue and organ levels
77
. They are 
implicated in cellular proliferation, migration, differentiation, apoptosis and cell-cell 
interactions
78-79
. They are important during embryogenesis and their expression in adults is 
strictly regulated
80
. All ETS protein members share a highly conserved DNA binding domain 
through which they bind to sequences containing a GGAA ‘core’ motif surrounded by bases that 
provide affinity and specificity to the interaction
81-82
. FLI1 is transcription factor with very 
restricted expression, especially during development, preferentially in hematopoietic and 
endothelial cells, and in the mesenchyme derived from neural crest cells
83
. In adult tissues FLI1 
remains expressed almost only in hematopoietic tissues. Fli1 as well as other ETS proteins are 
known to act both as activator as well as repressor of transcription having as targets oncogenes, 
tumor suppressor genes and genes related to apoptosis, differentiation, angiogenesis and 
invasion
78, 81, 84
. 
 
4.3.5 Cell of origin 
To understand ES it is crucial to address the issue of the cell of origin. Even though a substantial 
amount of work has been done on identification and characterization of the cell of origin there is 
still no clear answer to this question. There exist two hypotheses: 
 Mesenchymal stem cell as the cell of origin for ES 
 Neural crest stem cell as the cell of origin for ES. 
There are several observations going in favor of neural crest stem cell of origin
85-87
. First it was 
found that ES expressed cell surface antigens associated with the neuroectodermal lineage
86
. Both 
ES and peripheral primitive neuroectodermal tumor have the same t(11;22)(q24;q12) 
rearrangement suggesting they represent the same tumor with differences in extent of neural 
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differentiation
44, 88-89
. Finally, a gene expression profiling study showed that genes expressed in 
neural tissues or during neuronal differentiation are highly expressed in ES
87
. 
Regarding mesenchymal stem cells as the cell of origin, in the past few years there is a slight 
prevalence in favor of this theory that has been collaborated by growing amount of evidence
90-94
. 
Upon silencing of EWS/FLI1 in ES cell lines they displayed a mesenchymal stem cell (MSC) 
gene expression profile, and they were capable to differentiate along both osteogenic and 
adipogenic lineages
94
. Also, human MSCs provide an appropriate cellular context for EWS/FLI 
expression. Human MSCs retain the ability to propagate in the presence of the fusion protein 
unlike other normal human cell types when transfected with EWS/FLI1
93
. 
However, it is possible that these two theories are not mutually exclusive. One new idea arose 
that is encompassing both of these two cell types, suggesting that ES may arise from a neural 
crest stem cell exhibiting mesenchymal features or from a mesenchymal stem cell that is neural 
derived
95-96
. 
Regardless of which hypothesis is correct it is necessary to emphasize the importance of the 
appropriate cellular context for the study of EWS/FLI1 and its function. Despite the fact that 
EWS/FLI1 has transforming ability when transduced in NIH3T3 cells, expression of EWS/FLI1 
results in growth arrest in a variety of different cell types including primary human fibroblasts, 
mouse embryonic fibroblasts, immortalized rat fibroblasts, neural crest progenitor cells and 
rhabdomyosarcoma cells
97-98
. Further support for the importance of cellular context comes from 
the fact that when EWS/FLI1 is expressed in NIH3T3 cells it activates a different gene 
expression pattern from the one observed in ES cells
53
. Even putative cells of origin, namely 
human mesenchymal stem cells, fail to form tumors when expressing EWS/FLI1 and injected in 
immunodeficient mice
93
. Altogether, it is clear that for the tumor development not only 
EWS/FLI1 expression is necessary but also the appropriate cellular background with additional 
secondary hits. This is exactly the reason why there is still no animal model for ES since, apart 
from the issue of the right cell of origin, we don’t know what are the secondary hits necessary for 
ES development. 
4.3.6 EWS/FLI transcriptional regulation 
EWS-FLI1 acts as aberrant transcription factor by altering expression of target genes. Since many 
of its target genes contribute to tumorigenesis, substantial amount of work has been carried out to 
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elucidate both mechanisms of transcriptional regulation by EWS/FLI1 as well as to identify the 
crucial target genes for the biology of ES. Even though first studies classified EWS/FLI as a 
strong transcriptional activator
46, 65, 99-100
, later it was shown that it can also function as a 
transcriptional repressor
101-102
. Further expression profiling of ES cell lines confirmed the 
repressive capacity of EWS/FLI1
103-104
. Interestingly, among more than 1000 EWS/FLI-regulated 
genes in A673 cells, it appeared that down regulated targets comprised up to 80% and therefore 
the majority of the deregulated genes. However, more recent comprehensive transcriptional 
analyses comparing multiple ES cell lines and tumor samples discovered a more equal 
representation of EWS/FLI induced and repressed genes
105-107
. Several studies demonstrate the 
importance of target gene repression for the fully malignant phenotype and imply that this may be 
a critical EWS/FLI1 mediated activity
101, 103
. 
EWS/FLI1, like other ETS family members, is binding to DNA sequences containing a GGAA 
core motif surrounded by additional bases necessary for high affinity and specificity of the 
interaction
81-82
. Using in vitro binding site selection approaches it has been shown that both wild 
type FLI1 as well as EWS/FLI1 preferentially bind to ACCGGAAGTG sequence with high 
affinity
81, 108
. The binding of EWS/FLI1 to this sequence was confirmed also in vivo using ChIP 
on chip approach
109
. However, in the case of EWS/FLI1 up regulated target genes, GGAA-
containing microsatellite sequences have been identified as EWS/FLI-binding sites and this has 
been confirmed by ChIP-sequencing as well
110
. The identification of microsatellites as cancer-
relevant EWS/FLI-binding sites suggests that such elements have important roles in the 
development of ES despite the fact that microsatellite sequences are usually described as ‘junk 
DNA’ without biologic function111. The exact mechanism of how EWS/FLI1 is binding to these 
microsatellites is not fully elucidated but it might hold true for other  ETS family members
112
. 
The exact mechanism of EWS/FLI1 transcriptional activation and repression is not fully 
elucidated. Protein–protein interactions and post-translational modifications are probably 
involved in both activating and repressing functions of EWS/FLI1. In ES cell lines EWS/FLI1 
has been shown to be phosphorylated, and in a heterologous system phosphorylation modulates 
DNA binding and transcriptional activity, suggesting that phosphorylation may be important for 
the function of EWS/FLI1
113-114
. Other posttranslational modifications of EWS/FLI1, such as O-
GlcNAcylation might be involved in the regulation of EWS/FLI1 transcriptional activity
115
. 
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EWS/FLI1 interacts with proteins involved in the transcriptional process like RNA polymerase II 
subunit RPB7
72
. Apart from the basal machinery, EWS/FLI interacts with other transcriptionally 
relevant proteins, such as RNA helicase A
116
. Inhibition of this association with small molecules 
reduced tumor growth in xenograft mouse models, suggesting that this interaction is biologically 
relevant
117
. Using reporter assays it was shown that the RNA helicase A-EWS/FLI1 interaction 
increases transcriptional activity of EWS/ FLI1. However, the presence of RNA helicase A at the 
promoters of EWS/FLI1 repressed target genes doesn’t go along with these findings116. 
The mechanism of transcriptional repression by EWS/FLI1 is less clear. One explanation might 
be that interaction between EWS/FLI1 and p300 is inhibiting the histone acetyl-transferase 
activity of p300, thus blocking its transcriptional activation and resulting in transcriptional 
repression
102
. However, there is more evidence for an indirect repressive function of EWS/FLI1 
by up regulating expression of transcriptional repressors, such as NKX2.2, or co-repressors like 
NROB1
93, 118-119
. 
Genomic approaches linking RNAi technologies with microarray analysis have identified 
thousands of EWS/FLI1 deregulated genes in ES cell lines
103-104, 106-107
. However, only a hand full 
of genes have been validated as direct target genes of EWS-FLI1: hsRPB7
72
, UPP1
120
, tenascin-
C
121
, Id2
122
, p21WAF1/CIP1
123
, PTPL1
124
, phospholipase D2
125
, TGFBR2
101
, IGFBP3
126
, MK-
STYX
127
, TERT
128
, GLI1
126
, NR0B1
129
, caveolin-1
130
, EZH2
93
 and Aurora A and B
131
. Many 
more genes have been described but not confirmed to be direct targets, despite the fact they are 
involved in signaling pathways and gene regulation networks initiated by EWS-FLI1. These 
indirect target genes or yet to be validated target genes include: EAT-2
132
, MFNG
133
, mE2-C
134
, 
PIM3
135
, IGF1/IGF1R
136
, c-Myc and p57KIP2
137
, MAPT, PP1R1A, NEK2 andcyclin D1
138
, 
Skp2
139
, CD99
140
, zyxin
141
, cholecystokinin
142
, VEGF-A
143
, NKX2.2
104
,  NOTCH-p53
144
, 
thrombospondins1 and 2
145
 and TOPK
146
. Although not all of these genes are actively involved in 
the transformation process, some of them have been shown to be crucial for oncogenesis 
(NKX2.2, NR0B1and GLI1)
104, 107, 119, 147-149
. All three of these proteins have a role in 
transcriptional regulation. NKX2.2 is transcription factor that is a critical direct EWS-FLI1 target 
gene and required for ES oncogenic transformation
104
. Interestingly, the NKX2.2 transcriptional 
signature was found to consist exclusively of down-regulated genes that overlap with the 
EWSFLI1 repressed genes in ES
119
. This implies that at least to some extent EWS/FLI1 
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repressive function can be attributed to other transcriptional repressors that are directly 
upregulated by EWS/FLI1.  
In contrast to target genes involved in transcriptional regulation, other EWS/FLI1 target genes 
can be connected to hallmarks necessary for tumor formation and progression
150
. For example, 
expression of hTERT allows for tumor cell immortalization and expression of vascular 
endothelial growth factor allows vasculogenesis. Exactly these two genes are expressed in many 
ES tumors and cell lines
151-155
. Both of these genes have been shown to be induced by EWS/FLI 
in heterologous cellular backgrounds
152-153
.  
The role of many of EWS/FLI1 target genes has been elucidated by now. Up regulation of target 
genes like IGF1, MYC and NKX2.2, promotes cell proliferation and survival. At the same time 
inhibition of other target genes like p21, p57kip, TGFBR2 and IGFBP3 leads to escape from 
growth inhibition, senescence and apoptosis.  Taken together, EWS/FLI1 as a hallmark of ES 
through transcriptional regulation of many target genes drives tumor development, maintenance 
and progression. 
4.4 Treatment of Ewing sarcoma 
4.4.1 Multimodal treatment 
Before chemotherapy has been introduced, survival of ES patients was less than 10%, even 
though it was well known that this tumor type is very sensitive to radiotherapy. Today, in patients 
with localized disease by applying modern multimodal therapeutic regimens including induction 
chemotherapy and local control with surgery, radiotherapy or a combination of both modalities, 
cure rates of approximately 70% can be achieved. However, for patients with metastasis at 
diagnosis the prognosis is still very bad, indicating the limitations of current therapeutic 
approaches. Intensity of chemotherapy is of significant importance.  
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Table 2 Chemotherapy in ES (adapted from
156
) 
Starting with single-agent chemotherapy in the early 1960s, modern multiagent chemotherapeutic 
regimens have been developed
157
(Table 2). Ever since, a huge effort was undertaken to find 
optimal treatment strategies: actinomycin D, cyclophosphamide, and vincristine were introduced 
in the 1970s
158
; neoadjuvant chemotherapy concepts were first introduced by Rosen et al and 
consecutively developed by other groups
20, 159-161
. The benefit of additional anthracyclines was 
shown in the 1980s
17, 20, 162
. Since 1990 the standard neoadjuvant/adjuvant chemotherapy 
backbone consists of vincristine, actinomycin D, cyclophosphamide, and doxorubicin (VACD or 
VACA)
163
. In the meantime, a number of studies have been initiated with the goal to improve this 
standard protocol. In study INT-0091 conducted by the Pediatric Oncology Group–Children’s 
Cancer Group (POG-CCG),36518 ES patients were randomized to chemotherapy with VACD 
either alone or alternating with ifosfamide and etoposide (VACD-IE). Compared with VACD 
alone, the alternating VACD-IE regimen significantly improved 5-year event free survival (69% 
v 54%, P=0.005) and 5-year overall survival (72% v 61%, P=0.01). The European Inter-group 
Cooperative ES Study-92 (EICESS-92) compared the activity of VACA with a similar regimen in 
which cyclophosphamide was replaced with ifosfamide (VAIA) in 155 standard-risk patients
164
. 
The 3-year event free survival rates for VACA was 73% and for VAIA was 74%, thereby 
indicating that these two regimens have similar activity in ES. The only advantage of VAIA was 
that it induced less hematologic toxicity. The EICESS-92 study, in 492 high-risk patients, 
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compared VAIA with VAIA plus etoposide (EVAIA)
164
. However, this comparison showed only 
a non-significant 17% improvement in event free survival and a 15% improvement in overall 
survival among patients treated with EVAIA. Currently, the most widely used regimens contain 
vincristine, doxorubicin, and cyclophosphamide, with ifosfamide and etoposide with or without 
actinomycin D (Table 2). 
There are ongoing clinical trials that are supposed to establish whether the addition of high dose 
chemotherapy regimens followed by autologous haematopoietic stem cell rescue has some 
advantage. The current standard is, following biopsy-proven diagnosis, initiating four or five drug 
combination chemotherapy schema that isifosfamide and doxorubicin based. This treatment is 
continued following local treatment for a total duration of 10−12 months. The rationale for 
primary chemotherapy is to induce shrinkage of the primary tumor and thus facilitate local 
control, especially limb salvage surgery, which is easier to perform once an initial bulky soft-
tissue mass has disappeared under intense primary combination chemotherapy. With respect to 
the modality of local control, there is good evidence from various groups regarding the better 
control with surgical or combined surgical and radiotherapy modalities compared with definitive 
radiotherapy that bears a higher risk of local recurrence and secondary radiotherapy induced 
malignancies. However, this might be a biased result given the fact that definitive radiotherapy is 
usually used in difficult to resect large tumors that are not located in limbs but more often in 
pelvis and spine, sites difficult to resect which are associated with worse prognosis
165
. As a result 
of current intense combination chemotherapy regimens and careful interdisciplinary local therapy 
planning, with a preference for surgery or combined modality local control, long-term disease-
free survival in tumors of the extremities is approximately 80%
166
. However, pelvis remains the 
most difficult primary site. In this case patients usually already have a large mass at diagnosis and 
this is followed by further difficulties regarding appropriate surgery and radiation that all together 
contribute to worse prognosis
164, 167-168
. 
Nevertheless, the single most important adverse prognostic factor is presence of metastases at 
diagnosis. If the metastases are in the lungs, using lung irradiation appears to improve the 
outcome. In patients with multiple osseous metastases at diagnosis there is direct correlation 
between long term survival and the extent of disease within the skeletal system and expected long 
term survival is less than 10%
34, 169-170
. 
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4.4.2 Targeted treatment 
The aim of targeted therapy is to specifically eliminate tumor cells while at the same time normal 
cells remain less affected. ES cells, due to their unique properties, present quite good candidates 
for targeted therapy. The presence of EWS/FLI1 fusion protein only in the tumor cell 
distinguishes it from normal cells. At the same time, EWS/FLI1 alters expression of many target 
genes creating the fully malignant phenotype of the tumor cell leading to ‘oncogene addiction’, 
makes tumor cells dependent on its presence. Since EWS/FLI1 has these properties only in the 
permissive background, this implies dependency of the tumor cell on synergistic signaling 
pathways that cooperate in EWS/FLI1 permissive cellular background. 
4.4.2.1 Targeting EWS/FLI1 
Targeting oncogenic fusion proteins is quite promising since they represent unique molecular 
targets for tumor cell specific therapeutic development. Imatinib (Gleevec) as targeted inhibitor 
of the BCR-ABL fusion protein kinase provides proof of principle for this strategy and it 
completely revolutionized chronic myelogenous leukemia (CML) treatment. However, unlike 
kinases, the transcription factor fusion proteins that are present in sarcomas remain un-druggable. 
Reducing EWS-FLI1 levels by antisense oligodeoxynucleotides
171-173
, antisense RNA expressed 
from a vector
171, 174-175
, and small interfering RNA (siRNA) delivered via nanoparticles
173
, all 
inhibit the proliferation ES cell lines and xenografted tumors. However, the challenge of 
pharmacologic delivery still remains the main obstacle for the clinical translation of these 
macromolecule based strategies
176
. 
For pharmacological reasons small-molecule inhibitors of EWS-FLI1 function may be more 
favorable. However, since EWS/FLI1 lacks an intrinsic enzymatic activity finding a small 
molecule inhibitor is difficult. Cytosine arabinoside (ARA-C) has been identified in a small 
molecule screen as potential modulator of EWS-FLI1, and it was suggested to decrease 
EWS/FLI1 protein expression
177
. Being a promising candidate with longstanding experience for 
treatment of childhood leukemia, ARA-C has been rapidly translated into a phase II clinical trial. 
However, intermediate doses of ARA-C failed as a single agent in relapsed and refractory ES 
patients, having only minimal activity but profound toxicities
178
.  
Recent high-throughput screening of more than 50 000 compounds identified mithramycin as 
specific inhibitor of EWS/FLI1 activity
179
. The compound exhibited strong antiproliferative 
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effect in ES cell lines in low nM concentrations and also antitumor activity in vivo. Even though 
the mechanism of action is not known yet, Grohar et al. speculate that mithramycin is directly 
inhibiting EWS/FLI1 activity
179
.  
A potentially useful strategy to target EWS-FLI1 is disruption of key EWS-FLI1 protein-protein 
interactions since protein complexes have been suggested to regulate other ets-family proteins
180
. 
Even though disruption of protein-protein interactions is very challenging it seems that the 
therapeutic disruption of EWS-FLI1 transcriptional complexes might be feasible. RNA helicase 
A (RHA) has been identified as a protein that specifically binds EWS/FLI1, enhances EWSFLI1 
modulated transcription and cooperates in EWS-FLI1 oncogenic transformation
116
. Although the 
exact nature of RHA requirement for EWS-FLI1 function remains to be determined, small 
molecule inhibitors of RHA–EWS/FLI1 protein-protein interaction have been identified117. YK-
4-279 is small molecule that inhibits tumor growth in ES xenograft model. These data provide a 
first proof of principle that disruption of the interaction of a cancer specific oncogenic 
transcription factor with its normal cellular binding partners provides a strategy for tumor cell-
specific therapeutic development. 
4.4.2.2 Targeting Growth Factor signaling 
Growth factor signaling usually goes via cell surface receptors whose activity is ligand 
dependent. These receptors possess tyrosine kinase activity in their intracellular domains and 
when activated they transfer this signal to downstream signaling cascade of kinases. In many 
cancers RTKs are dysregulated so that they are constitutively active thus presenting very potent 
oncoproteins involved in development and progression of cancer. For this reason RTKs, their 
ligands and downstream signaling molecules with kinase activity are a focus for targeted drug 
development. 
4.4.2.3 Targeting the insulin-like growth factor-1 receptor (IGF1R) 
In solid cancers, the IGF1R gene is often amplified while at the same time ligand over expression 
is frequently observed, altogether resulting in enhanced signaling
181-182
. The contribution of the 
insulin-like growth factor (IGF) pathway to pathogenesis of ES has been extensively discussed
183-
184
. Binding of IGF-I to the insulin-like growth factor I receptor (IGF-IR) leads to activation of 
PI3K and MAPK pathways promoting proliferation
185
 (Figure 7). A link between IGF-I and ES 
has been implied also by epidemiological studies. The rising IGF-I levels in puberty coincide 
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with incidence of ES in this age, since ES most frequently occurs in the second decade of life
186-
188
. Therefore, it appears that IGF1R signaling is crucial for ES development. 
 
Figure 7 IGF1R signaling activation upon binding of ligands leads to activation of MAPK and PI3K pathways. Solid 
lines indicate direct interaction (adapted from
189
) 
Clinical efficacy of IGF1R blockage has a wide molecular basis in ES
180, 186
. In patients with 
metastatic disease and low IGF-I levels and high IGFBP3:IGF-I ratios a trend towards improved 
survival has been observed
187
. An IGF1/IGF1R autocrine circuit exists, where EWS/FLI1 up 
regulates IGF1 ligand as a direct target gene
190
. Molecular studies have shown that EWS/FLI1 
through aberrant transcription represses negative regulator of IGF1, insulin-like growth factor 
binding protein 3 (IGFBP3) thus increasing the bioavailability of IGF1
103
.  EWS/FLI1 also 
indirectly diminishes level of IGFBP3, in NIH3T3 cells and embryonic stem cells, through direct 
repression of transforming growth factor beta receptor type II (TGFβRII) expression. TGFβ was 
shown to induce IGFBP3
101, 191-192
. Also, for EWS-FLI1 transformation of fibroblasts a functional 
IGF1R signaling axis is necessary
193
. Blockage of IGF1R signaling in ES cells in vitro increases 
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sensitivity to conventional chemotherapeutics, leading to impaired tumor growth, metastasis, and 
angiogenesis in vivo
194-197
. 
All these findings are in good agreement with the basic presumption for targeted therapy and 
which in this case is existence of an ‘addiction’ to IGF1R signaling. Therefore, blocking IGF1R 
signaling should induce apoptosis in ES cells and spare the normal cells thus opening the 
possibility of tumor cell specific targeted approach. Interestingly, a similar IGF1R addiction has 
been observed for other fusion protein bearing childhood sarcomas, namely rhabdomyosarcoma 
and congenital fibrosarcoma
198-199
.  
Induction of apoptosis through inhibition of IGF-IR with a monoclonal antibody was observed as 
early as 1990
136, 200-201
. Based on all of the above, several IGF-IR antibodies have been developed 
and are being tested in phase I/II studies in ES patients. Human monoclonal IGF1R antibody 
AMG479 (ganitumab), in a phase I study, in patients with advanced solid tumors or non-Hodgkin 
lymphoma (NHL), induced complete response of more than 28 months in one ES patient
202
. In 
another study, the fully human monoclonal antibody R1507 (robatumumab) was well tolerated 
and showed activity in patients with advanced solid tumors, with good response in two ES 
patients
203
. And in a phase I study of the human monoclonal antibody CP-751,871 (figitumumab) 
in patients with advanced ES, 2/2 responses and 6/8 disease stabilizations were observed
196
. Since 
IGF1R blockage in combination with chemotherapeutics showed good results in preclinical 
settings, clinical studies addressing the combination treatments have been initiated and are still 
ongoing.  
However, huge expectations from IGF1R antagonists were not fulfilled so far, since only a 
minority of patients with advanced ES responds to IGF1R antagonists. Why is this the case is still 
unclear. There is a need for predictive molecular markers that would define the subset of patients 
likely to respond. Identification of such biomarkers would be beneficial for future clinical 
development of IGF1R antagonists since it would enable pre-selection of responsive patient 
populations
204
. Expression levels of IGF1R, IGF1, IGFBPs, are the main candidate biomarkers 
along with activation of downstream signaling effectors such as AKT
205-206
. Interestingly, genetic 
mutations within the IGF1R signaling pathway as molecular basis for sensitivity, have not been 
detected so far
182
.  It is possible that alternative signaling inputs bypass targeted IGF1R inhibition 
downstream of the cell surface receptor since similar resistance mechanisms have already been 
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observed in rhabdomyosarcoma mouse model
205
. Among these, co-activation of RTKs such as 
epidermal growth factor receptor (EGFR) and ERBB2 has been observed. Combined targeted 
treatment of both RTKs elicited enhanced antitumor activitiy
206-207
. Therefore, combined 
targeting strategies are now under clinical investigation. 
The future clinical development of IGF1R blocking agents for ES patients is under question. The 
main reason is low efficacy of IGF1R blocking agents observed in frequent cancer types such as 
breast cancer, colon carcinoma, and non-small cell lung cancer (NSCLC), causing decreased 
commercial interest in further development. Nevertheless, at the moment there are 82 IGF1R 
antagonist studies with 25 still recruiting (http://www.clinicaltrials.gov ). Future development 
will depend on the outcome of these ongoing studies. 
4.4.2.4 Targeting other receptor tyrosine kinases 
Targeting several RTKs in other types of cancer showed very good results, such as the use of 
imatinibin the treatment of patients with chronic myelogenous leukemia (CML) and 
gastrointestinal stroma tumors (GISTs). Therefore, the expression and role of RTKs in ES was 
subject of several investigations
208-211
. In ES platelet-derived growth factor receptor-β (PDGFRB) 
is expressed and it is suggested that it plays a role in cell proliferation and metastasis. Inhibition 
of PDGFRB by RNAi and a specific kinase inhibitor, AG1295, has been shown to impair cell 
growth and chemotaxis in vitro and in vivo
197, 212
. However, since there is no detectable 
expression/secretion of PDGFRB ligands in ES, this suggests a dependence on paracrine 
stimulation from the microenvironment
212
. Also, in contrast to other malignancies, where 
activating PDGFRB mutations are common, no mutations have been described in ES so far
213
. 
Nevertheless, PDGFRB seems to be a good candidate for targeted therapy. However, there are no 
specific inhibitors exclusively inhibiting PDGFRB. The BCR-ABL inhibitor imatinib (Gleevec) 
has emerged as a multikinase inhibitor for ABL, KIT, and PDGFRs. Also second-generation 
multikinase inhibitors such as sunitinib (Sutent), sorafenib (Nexavar) nilotinib (Tasigna), and 
dasatinib (Sprycel) are effective against PDGFRB
207
. However, the relevance of targeting the 
PDGF/PDGFRB axis in ES remains unclear, since only multikinase inhibitors have been used so 
far. c-KIT, receptor for stem cell factor (SCF), is another target of imatinib. It is expressed in 
over 30% of ES
214
. Despite expression, there was no significant effect observed
213
. In vitro, 
imatinib alone did not induce significant apoptosis, but had synergistic effect with vincristine and 
doxorubicin
215
.  One reason might be that in gastrointestinal stromal tumors, where Imatinib is 
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effective, mutations render Kit constitutively active. In ES these kind of activating mutations are 
rare. In two clinical trials Imatinib has been evaluated as single agent. In these phase II studies in 
sarcomas, 0/13 and 1/24 ES patients responded
216-217
. Therefore, it is hard to say whether 
PDGFRB and/or KIT present relevant targets in ES. 
4.4.2.5 Targeting intracellular kinases 
Activation of the mammalian target of rapamycin (mTOR) pathway is a very common event 
during tumorigenesis of several types of cancer
218
. In particular, strong preclinical evidence 
suggests a pivotal role of this pathway during the sarcomagenesis. Therefore, in childhood 
sarcoma models it was shown that the mTOR inhibitor rapamycin has activity against tumor 
growth
219
, which is probably a result of at least partial down-regulation of vascular endothelial 
growth factor (VEGF) expression and as consequence inhibition of angiogenesis
195
. Interestingly, 
in ES rapamycin is not only blocking cell proliferation in vitro, but was also shown to decrease 
EWS-FLI1 fusion protein expression
220
. At the moment there are several rapamycin derivatives 
in clinical development in phase I/II studies in childhood sarcomas, including RAD001 
(everolimus), CCI-779 (temsirolimus), and AP23573 (ridaforolimus). However, one problem 
with rapamycin is that inhibition of mTOR induces an IGF1R dependent feedback activation of 
AKT thus attenuating its effects
195, 197, 205, 218
. Possible combined inhibition of mTOR and IGF1R 
might be a logical step forward. Upon showing such synergistic effect of combined IGF1R 
inhibition and rapamycin in vitro as well as in vivo in different childhood sarcomas
195
, clinical 
phase I/II studies have been initiated and first results suggest a favorable toxicity profile
221
 
(http://www.clinicaltrials.gov ). 
Taken together, it is clear that even though there is an increasing knowledge about biology of ES, 
there is still lack of transfer of this knowledge to the clinics. Therefore, it is necessary to elucidate 
all the potential contributors to the pathogenesis of ES that would enable establishment of 
successful targeted therapy. 
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4.5 Aims of the thesis 
Given the fact that EWS/FLI1 is crucial for both ES development as well as tumor maintenance it 
was of great interest to establish an approach that would enable us to find compounds/inhibitors 
with activity against ES cells. Existing screening strategies did not show to be optimal for the 
discovery of inhibitors of EWS/FLI1 activity/expression. Therefore, the first aim of this thesis 
was to establish an expression based read-out system to measure modulation of transcriptional 
activity of EWS/FLI1 for small molecule discovery. The idea was to monitor activity of 
EWS/FLI1 by measuring expression of several EWS/FLI1 target genes and at the same time to 
measure proliferation of cells. Second aim was to apply this screening approach on a library of 
mainly FDA approved compounds to find compound(s) that can induce apoptosis in ES cells, 
followed by validation experiments including testing the effect of compound in xenografted mice. 
The third aim was to use the established screening approach to screen a small library that 
includes a broad range of kinase inhibitors thus covering all major signalling pathways in order to 
identify the molecular pathway(s) that may contribute to the transcriptional activity and/or 
expression of EWS/FLI1.   
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Abstract 
 
Ewing sarcoma (ES) is a group of malignancies affecting bone and soft tissue in childhood and 
adolescence. The biology of these very aggressive osteolytic tumors revolves around EWS/FLI1, 
a chimeric transcription factor that is considered to be a hallmark of ES and represents an 
ultimate therapeutic target. Considering the difficulties in finding small molecule inhibitors for 
transcription factors, the window of opportunity lays in the understanding of the cellular 
processes affecting or being affected by the fusion protein and thus providing secondary targeting 
points. Therefore, in order to identify molecular pathway(s) that may contribute to the 
transcriptional activity and oncogenic properties of EWS/FLI1, we performed screening of a 
small library of 153 targeted inhibitors covering all major signaling pathways. A673 cells were 
treated with 500nM concentration of inhibitors for 24 hours. Having expression of EWS/FLI1 
and its target genes PHLDA1, NROB1 and NKX2.2 as a read out, we discovered PI3K inhibitors 
as potent modulators of EWS/FLI1 expression. We confirmed this finding in four ES cell lines. 
To exclude the off target effect of the PI3K inhibitors we performed genetic loss of function 
experiments. Upon silencing catalytic subunits of PI3K we observed inactivation of the 
downstream signaling proteins followed by decrease of EWS/FLI1 on both mRNA and protein 
level. At the same time there was no effect of silencing PI3K on expression of FLI1 implying that 
the control of EWS/FLI1 expression is on the promoter level rather than at 3’ UTR. Analysis of 
the EWS/FLI1 promoter region using various deletion constructs in luciferase assays determined 
two 12bp minimal elements where transcription factor(s) under PI3K control is binding. 
Elucidating the direct link between PI3K and EWS/FLI1 is of importance, and identity of the 
responsible transcription factor(s) might provide novel therapeutic opportunities. 
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Introduction 
 
Ewing sarcoma (ES) is the second most frequent bone cancer in childhood. Clinically, ES 
appears as very aggressive osteolytic tumor with early tendency for development of metastasis. It 
belongs to the group of small-round-blue-cell tumors and is comprised of largely undifferentiated 
cells. The unique feature of this tumor is presence of the balanced t(11;22)(q24;q12) translocation 
in more than 85% of cases
1
. This gene rearrangement results in the expression of a chimeric 
fusion protein where RNA binding domain of EWS is exchanged by the DNA binding domain of 
the ets transcription factor FLI1, thus generating a dysregulated transcription factor EWS/FLI1
2
. 
More than 18 less represented alternative translocations involving EWS and other ets protein 
family members have been described since
3-8
. 
Extensive evidence supports the fact that EWS/FLI1 is an essential oncogenic component of ES 
development.  Its oncogenic activity is thought to be mediated through inappropriate regulation 
of target genes that are crucial for the fully malignant phenotype
9-14
. Apart from having 
transforming and tumorigenic potential, even more important is that EWS/FLI1 appears to be 
necessary for tumor cell maintenance
15-19
. For these reasons EWS/FLI1 represents an attractive 
target. However, it is widely accepted that transcription factors are ‘’undruggable’’, and 
EWS/FLI1 as intrinsically disordered protein is not prone to direct inhibition by a small molecule 
in the classical sense. 
No targeted agent has been routinely introduced into therapy of ES. Even though in the last few 
decades there has been considerable progress in both diagnosis as well as treatment of the 
localised disease, only 15% of patients with metastatic disease survive. Current treatment 
regimens of ES are not fully exploiting the fact that specific inhibition of signalling pathways is 
now possible. More specifically, it is not known whether specific pathway could affect the 
activity of EWS/FLI1.  
Considering the difficulties in finding small molecule inhibitors for transcription factors, the 
window of opportunity lays in the understanding of the cellular processes affecting or being 
affected by the fusion protein and thus providing secondary targeting points. Therefore, in order 
to identify molecular pathway(s) that may contribute to the transcriptional activity and oncogenic 
properties of EWS/FLI1 we used a screening approach as previously published
20
, and screened a 
small library that included a broad range of pathway inhibitors thus covering all major signalling 
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pathways. The aim of this study was to identify signalling pathways that are required for ES cell 
maintenance and thus provide novel indirect targeting options for EWS/FLI1. 
 
Material and Methods 
 
Cell lines 
 
Three type 1 (A673, SKNMC, TC71) and two type 2 ES cell lines (SKES, RDES) were used. 
TC71 cells were kindly provided by Prof H. Kovar (St-Anna Children’s Hospital, Vienna, 
Austria) and SKES and RDES by Prof. K.L. Schaefer (Institute of Pathology, Duesseldorf, 
Germany), A673 cells were purchased from the American Type Culture Collection (ATCC). 
Cells were cultivated on 0.1% gelatine coated plates (Sigma-Aldrich, Buchs, Switzerland) in 
RPMI medium supplemented with 10% FCS, 1% Penicillin/Streptomycin, 1% L-glutamine, at 
37°C in 5% CO2.  
 
Screening assay 
 
15 x 10
3
 cells were plated in 96-well plates 24h prior to treatment. A library of 153 commercially 
available latest targeted inhibitors in the field of oncology was acquired from Axon Medchem 
and Selleck chemicals LLC. The complete list of compounds is shown in the Supplemental Table 
1. Compounds were added to cells in complete RPMI medium at a final concentration of 500 nM 
for 24h. Lysis and subsequent cDNA synthesis was performed using Affinity Script QPCR 
cDNA Synthesis Kit (Agilent Technologies, #600559) according to the manufacturer’s protocol, 
followed by quantitative PCR (qPCR) with corresponding target probes as described below. 
Similarly treated 96-well plates were used to measure cell viability in parallel using WST-1 cell 
proliferation kit (Roche Applied Sciences, Rotkreuz, Switzerland).  
 
Quantitative PCR 
 
Quantitative PCR (qPCR) was performed under universal cycling conditions on an ABI 7900 
instrument using commercially available target probes and mastermix (all from Applied 
Biosystems, Rotkreuz, Switzerland). Data were analysed using SDS 2.2 software. CT values were 
normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Relative expression levels 
of the target genes were calculated using the CT method. All experiments were performed in 
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triplicate and repeated independently at least 3 times. Data analysis was done with the GraphPad 
prism software (San Diego, CA) and statistical analysis using the Student t-test. Commercially 
available target probes used were (Applied Biosystems): EFtype1:AIGI3UI, 
FLI1:Hs00956709_m1, PHLDA1:Hs00378285_g1, CAV1:Hs00184697_m1, 
NKX2.2:Hs00159616_m1, NR0B1: Hs03043658_m1, GAPDH:Hs99999905_m1, 
PIK3CA:Hs00907966_m1, PIK3CD:Hs00192399_m1, PIK3CG:Hs00277090_m1. 
 
Silencing of PI3K 
 
A total of 2 x10
6
 A673 cells were seeded in a 60 mm Petri dish.  On the same day, transfection 
was carried out using Lipofectamine RNAi MAX reagent (Invitrogen) and 5nM (final 
concentration) small interfering RNA (siRNA) of PI3K Cα (Ambion s10520), PI3K Cδ (Ambion 
s10530), PI3K Cγ (Ambion s10532). As a negative control scrambled siRNA no. 1 (Quiagen 
S103650318) was used. Cells were lysed 48 hours after silencing and subsequent RNA extraction 
using RNA easy mini kit (Quiagen) was performed followed by cDNA synthesis with RT kit 
(Applied Biosystems). 
 
Immunoblotting 
 
Cells were washed twice with PBS and harvested in lysis buffer containing 50mM NaH2PO4 
(pH=7.5), 150mMNaCl, 1% Triton X-100, 1mM Na3OV4, 5mM Na-pyrophosphate, 40nM NaF, 
1mM EGTA supplemented with protease inhibitor cocktail (Complete + 1mM EDTA, Roche). 
Protein concentration was determined by the method of Bradford (Biorad, Reinach, Switzerland). 
10–30µg of protein extract was resolved on 10% SDS-PAGE and transferred onto nitrocellulose 
membrane (Whatman, Germany). Primary antibodies were used as follows: anti-FLI1 
monoclonal antibody (Santa Cruz Biotechnologies, Santa Cruz, USA) (dilution 1:1000), anti-
PARP rabbit polyclonal antibody (Cell Signalling Technology, Berverly, MA, USA) (dilution 
1:1000), anti-pAKT antibody (Ser473, Cell Signalling) (dilution 1:1000), anti-AKT antibody 
(Cell Signalling) (dilution 1:1000), anti-PHLDA1 antibody (Sigma Aldrich)(1:1000), anti-
phospho-mTOR antibody (Ser2448, Cell Signalling) (1:1000), anti-mTOR antibody (Cell 
Signalling) (1:1000), anti-phospho-S6 Ribosomal protein antibody (Ser235/236, Cell Signalling) 
(1:2000),anti-S6 Ribosomal protein antibody (Cell Signalling) (1:1000) and anti-β-tubulin I 
mouse monoclonal antibody (Sigma-Aldrich) (dilution 1:40’000). After incubation with the 
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appropriate secondary peroxidase-conjugated antibodies (1:1’000), detection was performed with 
the ECL chemiluminescent reagent (Amersham Biosciences, Freiburg, Germany), according to 
the manufacturer’s instructions. 
 
Luciferase assays 
 
2.3kb of the promoter region of EWS/FLI1 (Ref. sequence NM_013986) (position -2239/+80 
relative to the transcription initiation site) was cloned into pGL4.19 luciferase vector (Promega) 
using the In Fusion HD Cloning Kit (Clontech Laboratories Inc.). Using the same approach 
several deletion constructs of the EWS/FLI1 promoter were constructed, namely -1708/+80, -
1277/+80, -774/+80, -275/+80 (position relative to the transcription initiation site). Using Site 
directed mutagenesis kit (Invitrogen) additional 24 deletion mutants of the -2239/+80 plasmid 
were made (detailed list of the plasmids with description of the mutations is in the Supplemental 
Table 2). 
2x10
3
 A673 cells per well were plated in 96-well plate and 24h later transfected using Jet Prime 
(Polyplus Transfection) with 100ng of reporter construct, or empty vector (pGL4.19) as a 
negative control.  The cells were also transfected with 10ng of Renilla luciferase plasmid for 
normalization of transfection efficiency.  After 24h cells were treated with 50nM BEZ235 or 
DMSO. 48h after transfection cells were lysed and assayed for luciferase activity using the Dual 
Glo luciferase reporter system (Promega) according to manufacturer’s instructions.  
 
Results 
 
 
Screening a small library of targeted inhibitors identifies PI3K pathway as 
modulator of EWS/FLI1 activity 
 
To identify molecular pathway(s) that might contribute to transcriptional activity and oncogenic 
properties of EWS/FLI1, we used our previously established and validated screening protocol
20
 to 
screen a second library of targeted inhibitors against a variety of molecular pathways. The 
collection of 153 inhibitors (Supplemental Table 1) was screened for EWS/FLI1 target gene 
modulation as primary read out in A673 ES cells at a final concentration of 500 nM in duplicates. 
Modulation of EWS/FLI1 transcriptional activity was monitored via expression of the specific 
target genes NR0B1
21
, PHLDA1
20
, NKX2.2
22
 and complemented by measuring EWS/FLI1 levels 
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itself. Since PHLDA1 is repressed and NROB1 and NKX2.2 are activated target genes of 
EWS/FLI1, inhibition of EWS/FLI1 activity is expected to result in up regulation of PHLDA1 
and down regulation of NROB1 and NKX2.2, independent of direct or indirect effects. 
Cytotoxicity measurement in duplicates using WST-1 assays was performed in parallel. The final 
hit-list is based on a significant (p<0.05, unpaired two-tailed t-test) modulation of at least two out 
of three target genes compared to the untreated controls in A673 cells. The results are 
summarized in the Figure 1 for the top 16 inhibitors. We identified inhibitors targeting several 
signalling pathways, both known and unknown to play a role in sarcomas. The most prominent 
among them is the phosphoinositide-3-kinase (PI3K) pathway, which is targeted by three 
different inhibitors.  Inhibition of this pathway provoked a significant modulation of EWS/FLI1 
target genes and a strong inhibition of cell proliferation in A673 ES cell line. Hence, these 
experiments identified PI3K signalling to modulate expression of EWS/FLI1 target genes. 
 
Figure 1 Screening a small library of targeted inhibitors identifies PI3K pathway as modulator of EWS/FLI1. 
Relative mRNA expression levels of EWS/FLI1 and target genes NR0B1, PHLDA1 and NKX2.2 in A673 cells after 
24h treatment with 500 nM of indicated compounds were measured by quantitative RT-PCR. Cell proliferation 
measurement using WST-1 assay was performed in parallel. Values are shown in percentage of untreated control 
(=100%) and represent mean of 2-4 independent experiments performed in duplicate. Significant values are written 
in bold (p<0.05, unpaired two-tailed student t-test). 
 
BEZ235 treatment alters EWS/FLI1 expression 
 
Since BEZ235, a dual inhibitor of PI3K and the downstream mammalian target of rapamycin 
(mTOR) with well described mode of action, was the only PI3K inhibitor to significantly 
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modulate all three EWS/FLI1 target genes, we validated the importance of this pathway further 
using this compound. Since our screening does not allow to discriminate between compounds 
with effects on activity or expression of EWS/FLI1, we addressed this question first. Upon 
treatment of four ES cell lines with 500nM BEZ235 we observed decrease to less than 50% of 
EWS/FLI1 expression on mRNA level (Figure 2A). This decrease of EWS/FLI1 levels was 
followed by corresponding response of its target genes, namely NKX2.2, NROB1 and PHLDA1. 
The effect of BEZ235 on EWS/FLI1 was confirmed also on protein level (Figure 2B) with a clear 
dose dependency. This also corresponded with induction of apoptosis, as measured by PARP 
cleavage. Hence, this data suggest that inhibition of PI3K signalling reduces expression of 
EWSFLI1 on both RNA and protein level. 
 
Figure 2 BEZ235 affects EWS/FLI1 levels (A) Relative expression of EWS/FLI1 and its target genes measured by 
quantitative RT-PCR upon 24h treatment with 500nM BEZ235 (B) Protein expression measured by western blot of 
EWS/FLI1, PHLDA1, PARP and β-tubulin as loading control. Cells were treated for 24h with indicated 
concentrations of BEZ235. 
 
 
 
 
Silencing PI3K pathway has effect on EWS/FLI1 expression 
 
Treatment with BEZ235 revealed significant changes in PHLDA1, NR0B1 and NKX2.2 
expression on the mRNA level. To exclude unspecific off-target effects of the drug we performed 
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genetic-loss of function experiments using siRNA targeting the catalytic domains α, δ and γ of 
class I PI3Ks in A673 cells. Treatment for 48 hours resulted in down regulation of PI3KC α, δ 
and γ mRNA by 75% as measured by quantitative RT-PCR (Figure 3A), compared to scrambled 
control. In PI3K silenced cells PHLDA1 showed a 10 fold up regulation, whereas target genes 
NR0B1, NKX2.2 and CAV1 were down regulated by 70%, 55% and 45%, respectively (Figure 
3B). Notably, expression of EWS/FLI1 was down regulated by 65%, as well only a minor effect 
was observed for FLI1 (7% down regulation), which was used as negative control to exclude a 
general impact of BEZ235 on gene expression. These results could be confirmed by western-blot 
analysis. Silencing of PI3K pathway also led to inhibition of the downstream effectors AKT, 
mTOR and S6 ribosomal protein as shown by phospho-specific antibodies and as expected 
(Figure 3C). Altogether, silencing of PI3Ks elicited the same effect on expression of EWS/FLI1 
and its target genes as did treatment with BEZ235 thereby validating the use of BEZ235 as 
specific inhibitor in further experiments.  
 
Figure 3 Modulation of EWS/FLI1 and target genes after PI3K pathway silencing. (A) PI3KC α,δ and γ mRNA 
expression levels were measured in A673 cells after silencing for 48h compared to scrambled control by qRT-PCR. 
(B) EWS/FLI1 and its target genes mRNA expression upon silencing of PI3KC α, δ and γ in A673 cells for 48 hours. 
    71 
 
(C) EWS/FLI1, PHLDA1 and PI3K downstream effectors expression levels after silencing in A673 cells for 48 
hours (numbers on the left and right side of the blot represent intensity of bands measured by densitometry) 
 
PI3K signalling regulates EWS/FLI1 expression on its promoter level 
 
Considering that FLI1 levels did not change upon inhibiting the PI3K pathway while at the same 
time EWS/FLI1 expression was reduced, we hypothesized that regulation of EWS/FLI1 occurs 
on the promoter level. To test this we performed a luciferase assay with a plasmid containing the 
2.3kb promoter of EWS in front of the reporter. Since BEZ235 has strong pro apoptotic effect on 
ES cells with IC50 at 498nM (Supplemental Figure 1), we first determined the minimal 
concentration capable to elicit a 2 fold decrease in luciferase activity as seen with endogenous 
EWS/FLI1 levels. A673 ES cells were transfected with 2.3kb promoter construct and 
concentration of BEZ235 titrated for 24h (Figure 4A). With increasing concentration of BEZ235 
we observed dose dependent decrease in the luciferase activity. At the same time, already 50nM 
BEZ235 treatment was able to reduce luciferase activity by 50% which was used for further 
experiments. Nevertheless, these experiments imply that indeed this promoter region contains a 
regulatory element responsive to PI3K signalling. To narrow down the region of interest we 
designed several additional deletion constructs. The results show that the regulatory element is 
still present within the smallest deletion construct (-275bp relative to the transcription initiation 
site). To exclude possible effects of BEZ235 on the stability of luciferase itself, cells were also 
transfected with a constitutive promoter of luciferase. Evidently, the compound did not interfere 
with luciferase activity (Figure 4B). 
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Figure 4 EWS/FLI1 promoter analysis by luciferase assay (A) Relative luciferase activity in A673 cells 
transfected with different constructs (pGL4.19-empty vector control, pGL3- constitutive promoter control, EWSR1-
Luc- 2.3kb promoter vector) and treated for 24h with different concentration of BEZ235 (B) Relative luciferase 
activity in A673 cells transfected with different deletion constructs of EWS/FLI1 promoter. Cells were treated with 
either DMSO or 50nM BEZ235 (C) Scheme of the cloning process for making sequential 12bp deletion constructs 
from the 2.3kb promoter construct (D) Luciferase assay performed as above, with a series of deletion constructs of 
the 2.3kb EWS/FLI1 promoter (E) Sequences of the two minimal binding elements that are absent from the deletion 
constructs Del2 and Del23. 
In order to pinpoint further the regulatory element within -275/+80 region of the promoter, we 
designed a series of deletion constructs where 12-14bp were deleted from the full size promoter 
(Figure 4C). If the regulatory element is excised from the promoter we expect that control by 
PI3K pathway is lost and hence there should be no difference in luciferase activity upon 
treatment with BEZ235. Out of 24 constructs only two, construct number 2  and construct 
number 23 were no more affected by the treatment with BEZ235, implying that the PI3K 
regulatory elements are within these  two 12bp sequences (Figure 4D and Supplementary table 
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2). The sequence of these elements that contain the responsive element is shown in Figure 4E. In 
summary, our results suggest that inhibition of PI3K pathway, through control of a transcription 
factor(s) that binds in a 12bp minimal element, can interfere with expression of EWS/FLI1 on the 
mRNA level. 
 
Discussion 
 
Despite increasing efforts there is still no successful targeted therapy for ES. Recently, several 
novel targeted approaches have been initiated in clinical trials
23-27
. However, it is clear that 
complexity of ES is not caused by a single driving event and therefore it is necessary to elucidate 
all the major contributors to the fully malignant phenotype. This approach should offer 
possibilities for several therapeutic targets and in combination therapy it should be possible to 
circumvent potential resistance to any given single drug. 
Here, we conducted a screening of a small library of targeted inhibitors that are inhibiting 
different signaling pathways in order to identify critical pathways. We employed our well 
established screening approach that uses expression of three EWS/FLI1 target genes as surrogate 
markers of EWS/FLI1 activity
20
 and was therefore an important simplification of the previously 
applied gene expression based high-throughput screening
28
. Nevertheless, the system represents a 
more targeted approach than screenings based on survival or proliferation only, and is more 
robust than a screening approach based on a single-gene reporter assay
29
. Given the fact that 
EWS/FLI1 expression is crucial for tumor cell maintenance, diminished activity/expression 
should also result in apoptosis and reduced cell proliferation
15-19
. As the most prominent pathway 
that regulates EWS/FLI1 activity/expression we identified the PI3K. This corroborates earlier 
findings demonstrating that IGF1R signaling via PI3K is a very important axis in ES cells
30-33
. 
Indeed, inhibition of IGF1R using monoclonal antibodies showed good initial response in a 
subgroup of patients. IGF1R activates several signaling pathways, whereas MAPK pathway is 
crucial for cell proliferation and PI3K pathway for anti-apoptotic effect
34
. Combined therapy of 
anti IGF1R antibodies and PI3K/mTOR inhibitors showed improved response. Nevertheless, 
even in these patients resistance was observed. This implies that alternative pathways are taking 
over thus providing tumor cell survival. 
Using BEZ235, a dual PI3K and mTOR inhibitor, as the most potent compound in our hit list we 
observed a strong decrease in EWS/FLI1 on both RNA and protein level. Surprisingly, very little 
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is known about the regulation of EWS/FLI1 expression. So far, only one study is available 
suggesting possible regulatory transcription factors
35
. However, it has been shown previously that 
inhibition of mTOR by rapamycin decreases EWS/FLI1 protein levels
36
. Therefore, we validated 
BEZ235 with genetic-loss of function experiments in order to exclude unspecific off-target 
effects. These experiments demonstrated that the effect on the EWS/FLI1 expression is specific. 
Moreover, by performing a series of luciferase experiments with the EWS/FLI1 promoter we 
showed for the first time the direct control of EWS/FLI1 promoter and thus its expression by the 
PI3K pathway. Further on, we were able to determine the exact regulatory element within the 
promoter. Additional studies are now necessary to determine the identity of the transcription 
factor(s) under PI3K control that is binding in this region. Computational analysis of the 
sequence using weight matrices implies several potential binding factors, both known as well as 
unknown to be controlled by the PI3K pathway. One of the candidates is NF-κB whose activity 
and intracellular localization is known to be controlled by PI3K signaling. However, further 
experimental confirmation is needed. 
Targeted inhibition of IGF1R/PI3K signaling shows very promising results for treatment of ES
23, 
25-26, 37
. However, we still do not know the exact mechanisms responsible for this efficacy. It 
seems there is a need for more direct targeting of EWS/FLI1 since it appears that silencing 
EWS/FLI1 has stronger pro apoptotic effect than IGF1R antibody
38
. One possible explanation is 
that IGFBP3 as target of EWS/FLI1 can induce apoptosis independently of IGF system
39
. Also, 
there are other EWS/FLI1 target genes that might contribute to induction of apoptosis upon 
silencing EWS/FLI1. Considering all this, it is possible that apoptosis induced by BEZ235 or 
other IGF1R/PI3K inhibitors is at least partially a result of decrease in EWS/FLI1 expression. 
Therefore, elucidating the direct link between PI3K and EWS/FLI1 is of importance, and identity 
of the responsible transcription factor(s) might provide novel therapeutic opportunities. 
 
 
 
 
 
 
 
 
 
    75 
 
 
References 
 
 1. Turc-Carel C, Aurias A, Mugneret F, Lizard S, Sidaner I, Volk C, Thiery JP, 
Olschwang S, Philip I, Berger MP, et al. Chromosomes in Ewing's sarcoma. I. An evaluation of 
85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 1988;32:229-
38. 
 2. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, 
de Jong P, Rouleau G, et al. Gene fusion with an ETS DNA-binding domain caused by 
chromosome translocation in human tumours. Nature 1992;359:162-5. 
 3. Jeon IS, Davis JN, Braun BS, Sublett JE, Roussel MF, Denny CT, Shapiro DN. A 
variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. 
Oncogene 1995;10:1229-34. 
 4. Kaneko Y, Yoshida K, Handa M, Toyoda Y, Nishihira H, Tanaka Y, Sasaki Y, Ishida 
S, Higashino F, Fujinaga K. Fusion of an ETS-family gene, EIAF, to EWS by t(17;22)(q12;q12) 
chromosome translocation in an undifferentiated sarcoma of infancy. Genes Chromosomes 
Cancer 1996;15:115-21. 
 5. Ng TL, O'Sullivan MJ, Pallen CJ, Hayes M, Clarkson PW, Winstanley M, Sorensen 
PH, Nielsen TO, Horsman DE. Ewing sarcoma with novel translocation t(2;16) producing an in-
frame fusion of FUS and FEV. J Mol Diagn 2007;9:459-63. 
 6. Peter M, Couturier J, Pacquement H, Michon J, Thomas G, Magdelenat H, Delattre O. 
A new member of the ETS family fused to EWS in Ewing tumors. Oncogene 1997;14:1159-64. 
 7. Shing DC, McMullan DJ, Roberts P, Smith K, Chin SF, Nicholson J, Tillman RM, 
Ramani P, Cullinane C, Coleman N. FUS/ERG gene fusions in Ewing's tumors. Cancer Res 
2003;63:4568-76. 
 8. Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second 
Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription 
factor, ERG. Nat Genet 1994;6:146-51. 
 9. Bailly RA, Bosselut R, Zucman J, Cormier F, Delattre O, Roussel M, Thomas G, 
Ghysdael J. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion 
protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 1994;14:3230-
41. 
 10. Hahm KB. Repression of the gene encoding the TGF-beta type II receptor is a major 
target of the EWS-FLI1 oncoprotein. Nat Genet 1999;23:481. 
 11. Lessnick SL, Braun BS, Denny CT, May WA. Multiple domains mediate 
transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene. Oncogene 1995;10:423-31. 
    76 
 
 12. May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, Lunsford LB, Hromas R, 
Denny CT. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional 
activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 1993;13:7393-8. 
 13. Nakatani F, Tanaka K, Sakimura R, Matsumoto Y, Matsunobu T, Li X, Hanada M, 
Okada T, Iwamoto Y. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic 
fusion protein. J Biol Chem 2003;278:15105-15. 
 14. Ohno T, Rao VN, Reddy ES. EWS/Fli-1 chimeric protein is a transcriptional 
activator. Cancer Res 1993;53:5859-63. 
 15. Kovar H, Aryee DN, Jug G, Henockl C, Schemper M, Delattre O, Thomas G, Gadner 
H. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth 
Differ 1996;7:429-37. 
 16. Maksimenko A, Lambert G, Bertrand JR, Fattal E, Couvreur P, Malvy C. Therapeutic 
potentialities of EWS-Fli-1 mRNA-targeted vectorized antisense oligonucleotides. Ann N Y 
Acad Sci 2003;1002:72-7. 
 17. Ouchida M, Ohno T, Fujimura Y, Rao VN, Reddy ES. Loss of tumorigenicity of 
Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene 
1995;11:1049-54. 
 18. Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y. EWS-Fli1 antisense 
oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive 
neuroectodermal tumor cells. J Clin Invest 1997;99:239-47. 
 19. Toretsky JA, Connell Y, Neckers L, Bhat NK. Inhibition of EWS-FLI-1 fusion protein 
with antisense oligodeoxynucleotides. J Neurooncol 1997;31:9-16. 
 20. Boro A, Pretre K, Rechfeld F, Thalhammer V, Oesch S, Wachtel M, Schafer BW, 
Niggli FK. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and 
cell survival in Ewing's sarcoma. Int J Cancer 2012. 
 21. Mendiola M, Carrillo J, Garcia E, Lalli E, Hernandez T, de Alava E, Tirode F, 
Delattre O, Garcia-Miguel P, Lopez-Barea F, Pestana A, Alonso J. The orphan nuclear receptor 
DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors. 
Int J Cancer 2006;118:1381-9. 
 22. Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, Golub TR, Lessnick SL. 
Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. 
Cancer Cell 2006;9:405-16. 
 23. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors 
in oncology: early clinical trial results and future directions. Oncogene 2009;28:3009-21. 
 24. DuBois SG, Krailo MD, Lessnick SL, Smith R, Chen Z, Marina N, Grier HE, 
Stegmaier K. Phase II study of intermediate-dose cytarabine in patients with relapsed or 
    77 
 
refractory Ewing sarcoma: a report from the Children's Oncology Group. Pediatric Blood & 
Cancer 2009;52:324-7. 
 25. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, 
Batzel GN, Yin D, Pritchard-Jones K, Judson I, Worden FP, Gualberto A, et al. Safety, 
pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-
751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. 
Lancet Oncol 2010;11:129-35. 
 26. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, Murphy 
B, Roth B, McCaffery I, Gorski KS, Kaiser B, Zhu M, et al. Phase I, pharmacokinetic, and 
pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth 
factor receptor 1. J Clin Oncol 2009;27:5800-7. 
 27. Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM, Adamson PC. 
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a 
Children's Oncology Group study. Pediatric Blood & Cancer 2008;50:254-8. 
 28. Zucman J, Melot T, Desmaze C, Ghysdael J, Plougastel B, Peter M, Zucker JM, 
Triche TJ, Sheer D, Turc-Carel C, et al. Combinatorial generation of variable fusion proteins in 
the Ewing family of tumours. EMBO J 1993;12:4481-7. 
 29. Ewan K, Pajak B, Stubbs M, Todd H, Barbeau O, Quevedo C, Botfield H, Young R, 
Ruddle R, Samuel L, Battersby A, Raynaud F, et al. A useful approach to identify novel small-
molecule inhibitors of Wnt-dependent transcription. Cancer Res 2010;70:5963-73. 
 30. Rikhof B, de Jong S, Suurmeijer AJ, Meijer C, van der Graaf WT. The insulin-like 
growth factor system and sarcomas. J Pathol 2009;217:469-82. 
 31. Scotlandi K, Benini S, Nanni P, Lollini PL, Nicoletti G, Landuzzi L, Serra M, Manara 
MC, Picci P, Baldini N. Blockage of insulin-like growth factor-I receptor inhibits the growth of 
Ewing's sarcoma in athymic mice. Cancer Res 1998;58:4127-31. 
 32. Scotlandi K, Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr 
Opin Oncol 2008;20:419-27. 
 33. Toretsky JA, Steinberg SM, Thakar M, Counts D, Pironis B, Parente C, Eskenazi A, 
Helman L, Wexler LH. Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in 
patients with Ewing sarcoma family of tumors. Cancer 2001;92:2941-7. 
 34. Benini S, Manara MC, Cerisano V, Perdichizzi S, Strammiello R, Serra M, Picci P, 
Scotlandi K. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant 
behavior of Ewing's sarcoma cells: therapeutic prospects. Int J Cancer 2004;108:358-66. 
 35. Moller E, Mandahl N, Iliszko M, Mertens F, Panagopoulos I. Bidirectionality and 
transcriptional activity of the EWSR1 promoter region. Oncol Rep 2009;21:641-8. 
    78 
 
 36. Mateo-Lozano S, Tirado OM, Notario V. Rapamycin induces the fusion-type 
independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell 
proliferation. Oncogene 2003;22:9282-7. 
 37. Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, Eckhardt SG, Eid 
JE, Greig G, Habben K, McCarthy CD, Gore L. A phase I study of weekly R1507, a human 
monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced 
solid tumors. Clin Cancer Res 2010;16:2458-65. 
 38. Huang HJ, Angelo LS, Rodon J, Sun M, Kuenkele KP, Parsons HA, Trent JC, 
Kurzrock R. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and 
EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis. PLoS One 
2011;6:e26060. 
 39. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of 
Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-
like growth factor binding protein 3. Mol Cell Biol 2004;24:7275-83. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    79 
 
 
 
 
 
 
Supplementary Data 
 
 
Supplemental Table 1: List of targeted inhibitors used 
in the screening 
No. Name Target 
1 [Ala92]-p16 (84-103) Cdk inhibitor 
2 17-AAG Hsp90 inhibitor 
3 2-Deoxy-D-glucose Glycolysis inhibitor 
4 3-MA Vps34 inhibitor (class III PI3K) 
5 A 769662  AMPK activator  
6 ABT-102  TRVP1 antagonist  
7 ABT-737 BCL-2, BCL-xl inhibitor 
8 AEG 3482  JNK inhibitor  
9 AG 013736 - Axitinib  VEGFR inhibitor  
10 AMD3100 CXCR4 inhibitor 
11 AMN 107 (Nilotinib)  BCR-ABL inhibitor  
12 Apratastat  TACE/MMP inhibitor  
13 AS 252424  PI3K p110 gamma inhibitor  
14 AT9283 Aurora kinases Inhibitor 
15 Atazanivir  Protease inhibitor  
16 AZD 2281 - Olaparib  PARP inhibitor  
17 AZD 7762  CHK inhibitor  
18 AZD1152-HQPA Aurora B inhibitor 
19 BACE 1 inhibitor  Beta Secretase inhibitor 
20 Bax inhibitor peptide P5 Bcl-2 Protein Family Inhibitor 
21 Bax inhibitor peptide V5 Bcl-2 Protein Family Inhibitor 
22 Bax inhibitor peptide,negative control Bcl-2 Protein Family Inhibitor 
23 BAY 61-3606 Syk inhibitor 
24 BI 2536  PLK-1 inhibitor  
25 BMS 189961  RAR gamma agonist  
26 BMS 270394  RAR gamma agonist  
27 BMS-345541 IκB inhibitor 
28 Bosutinib (SKI 606)  BCR-ABL/SRC inhibitor  
29 Butabindide  TPPII inhibitor  
30 BX 795  PDK1/TBK1 inhibitor  
31 BX 912  PDK1 inhibitor  
32 BZ - Gamma Secretase inhibitor BZ  Gamma Secretase inhibitor   
33 Cediranib  VEGFR inhibitor  
34 CH 55  RAR alpha/beta agonist  
35 Chir98014  GSK-3 inhibitor  
36 CI-1033 - Canertinib  EGFR inhibitor  
37 Combretastatin-A4 (CA-4)  Inhibitor of tubulin polymerization  
38 Compound C AMPK inhibitor 
39 CP 690550  JAK3 inhibitor  
40 CT 99021 - CHIR 99021  GSK-3 inhibitor  
41 Cyclopamine Hedgehog Pathway Inhibitor 
42 Cyclosporine Immunosupressant 
43 DAPT  Gamma Secretase inhibitor   
44 Dasatinib  BCR-ABL/SRC inhibitor  
45 DBZ  Gamma Secretase inhibitor   
46 Deguelin  Anticancer agent  
47 DM 3189  BMP inhibitor 
48 Doramapimod  p38 MAPK inhibitor  
49 DR 2313  PARP inhibitor  
50 FK 866  NAPRT1 inhibitor, anti-cancer agent  
51 GDC 0879  B-Raf inhibitor  
52 GDC 0941  PI3K inhibitor  
53 GDC-0449 Hedgehog Pathway Inhibitor 
54 Gefitinib EGFR inhibitor  
55 GSK 269962A  ROCK1 inhibitor  
56 GW 441756  TrkA inhibitor  
57 GW 786034  VEGFR/KIT/PDGFR inhibitor  
58 GW 843682X  PLK inhibitor  
59 Honokiol pAkt, scr, p44/42 MAPK 
60 HU-308  CB2 agonist  
61 IGC-001 Beta-Catenin inhibitor 
62 Imatinib  BCR-ABL inhibitor  
63 JAK inhibitor I JAKs inhibitor 
64 JIP-1 (153-163) JNK Inhibitor 
65 JWH 018  CB2 agonist  
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66 JWH 073  CB1/2 agonist  
67 JWH 133  CB2 agonist  
68 Ko 143  BCRP inhibitor  
69 KU-55933 ATM inhibitor 
70 L-685,485  Gamma Secretase inhibitor   
71 L-aminoadipic acid Glutamine synthase inhibitor 
72 Lamotrigine  Glutamate antagonist  
73 Lapatinib  EGFR/ErbB-2 inhibitor  
74 LE-135  RAR beta antagonist  
75 LY 2157299  TGF beta receptor inhibitor  
76 LY 294002  PI3K inhibitor  
77 Masitinib mesylate  KIT/PDGFR inhibitor  
78 MK 1775  Wee1 inhibitor  
79 MK-2206 Akt inhibitor 
80 MLN8237 Aurora kinase inhibitor 
81 Myoseverin  Microtubule inhibitor  
82 Na-Butyrate HDAC inhibitor 
83 NEC-1 Necroptosis/RIPK inhibitor 
84 NF-kB Inhibitor NF-kB Inhibitor 
85 Nocodazole Cell cycle G2/M inhibitor 
86 NSC 348884  Nucleophosmin inhibitor  
87 NSC 625987  CDK4 inhibitor  
88 NU 1025  PARP inhibitor  
89 NU 7441  DNA-PK inhibitor  
90 NVP-AEW514  IGF-1R inhibitor 
91 NVP-AUY922 HSP90 inhibitor 
92 NVP-BAG956  PI3K/PDK1 inhibitor  
93 NVP-BEZ235  PI3K/mTOC inhibitor  
94 NVP-BGJ398  FGF-R inhibitor 
95 NVP-BKM120 PI3K, not mTOC inhibitor 
96 NVP-BSK805 JAK2 inhibitor 
97 NVP-TAE684  ALK inhibitor  
98 NVP-TKI258 FGF-R inhibitor 
99 Obatoclax Bcl-2 inhibitor 
100 OSI 774 - Erlotininb  EGFR inhibitor  
101 OSI-027 mTORC1/2 inhibitor 
102 Palmitoylethanolamide  Endocannabinoid  
103 PD 0325901  MEK inhibitor  
104 PD 166793  MMP inhibitor  
105 PD 169316  p38 MAPK inhibitor  
106 PD 180970  Src kinase inhibitor   
107 PD 184352  MEK 1 inhibitor  
108 PD 98059  MEK inhibitor  
109 PD150606 Calpain inhibitor 
110 PF-00356231  MMP-12 inhibitor  
111 PHA-739358(Danusertib) Aurora kinases,Bcr-Abl and FGFR inhibitor 
112 PI 103  Class I PI3K inhibitor  
113 piceatannol Syk inhibitor 
114 PIK 75  PI3K p110 alpha inhibitor  
115 PIK 90  PI3K p110 alpha inhibitor  
116 pimecrolimus Calcineurin inhibitor 
117 PLX 4720  B-Raf inhibitor  
118 PP2 Src inhibitor 
119 PP242 mTORC1/2 inhibitor 
120 PU-H71 HSP90 inhibitor 
121 Roscovitine/Celiciblib Cdk inhibitor 
122 Ruboxistaurin (LY333531)  PKC beta inhibitor  
123 S31-201 Stat3 Inhibitor 
124 Saracatinib  Src and Abl inhibitor  
125 SB 202190  p38 MAPK inhibitor  
126 SB 203580  p38 MAPK inhibitor  
127 SB 216763  GSK-3 inhibitor  
128 SB 431542 TGF beta receptor inhibitor 
129 Scriptaid HDAC inhibitor 
130 SD 169  p38 MAPK inhibitor  
131 SD 208  TGF-betaR receptor 1 inhibitor  
132 SL 327  MEK1/2 inhibitor 
133 SNS-314 Aurora kinase inhibitor 
134 Sorafenib (BAY 43-9006)  Raf/Mek/Erk inhibitor  
135 Stobadine  Antioxidant  
136 SU 6656  Src kinase inhibitor  
137 SU11274 c-Met inhibitor 
138 Sunitinib - SU 11248  Multiple RTK inhibitor  
139 Tacrolimus Calcineurin inhibitor 
140 Tandutinib  FLT3 inhibitor  
141 TG101348 JAK2 (Flt3) inhibitor 
142 TGX 221  PI3K p110 beta inhibitor  
143 Tiplaxtinin  PAI-1 inhibitor  
144 TW-37 Bcl-2 protein family inhibitor 
145 Tyrphostin AG 490  JAK2 inhibitor  
146 U 73122  Phospholipase C inhibitor  
147 Vandetanib VEGFR/EGFR Inhibitor 
148 Velcade Proteasome inhibitor 
149 Vorinostat/SAHA HDAC inhibitor 
150 VPA HDAC inhibitor 
151 xav-939  Wnt/beta-catenin signal transd. inhibitor 
152 XL228 Multiple Tyr-kinase inhib. (IGF1-R, Bcr-Abl) 
153 Y-27632 p160 ROCK inhibitor 
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Supplemental Table 2: Deletion constructs of the 2.3kb EWS/FLI1 
promoter construct 
Name of the 
construct  
Position of the deletion relative to the transcription 
initiation site 
Del1 -214/-203 
Del2 -202/-191 
Del3 -190/-179 
Del4 -178/-167 
Del5 -166/-155 
Del6 -154/-143 
Del7 -142/-131 
Del8 -130/-119 
Del9 -118/-107 
Del10 -106/-95 
Del11 -94/-83 
Del12 -82/-71 
Del13 -70/-59 
Del14 -58/-47 
Del15 -46/-35 
Del16 -34/-23 
Del17 -22/-11 
Del18 -10/+2 
Del19 +3/+14 
Del20 +15/+26 
Del21 +27/+40 
Del22 +41/+54 
Del23 +55/+68 
Del24 +69/+80 
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Supplemental Figure 1 A673 ES cells viability after 24h treatment with titrating concentration 
of BEZ235 
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5.3  Additional studies: Functional relevance of 
PHLDA1 repression in Ewing sarcoma 
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Introduction 
PHLDA1 (Plekstrin homology-like domain, family A, member 1), also known as TDAG51 (T-
cell death-associated gene 51) belongs to a family of proteins (together with PHLDA2 and 
PHLDA3) and they all have in common a motif that resembles pleckstrin homology (PH) 
domain. Despite the fact that proteins with pleckstrin homology-like domains are often involved 
in different cellular processes such as cell adhesion, modulation of cell morphology or apoptosis, 
the function of PHLDA1 is still not fully elucidated. For the first time PHLDA1 was described in 
mouse T cell hybridoma where stimulation with antigen or an anti-T cell receptor antibody 
induced production of IL-2
222
. At the same time, mouse T cell hybridoma underwent Fas-FasL 
interaction dependent apoptosis. It was showed that PHLDA1 is required for mouse Fas (CD95) 
expression
222
. However, in humans this mechanism was not confirmed.  When constitutively 
expressed in various cellular models of PHLDA1 is associated with an increase of basal 
apoptosis, reduced cell growth, cloning efficiency and colony formation
223-226
. PHLDA1 is 
hypothesized to play a role in inhibition of translation
227
 and it binds proteins that are involved in 
RNA processing like lL14, eIF3-p66 or inducible polyA binding protein (iPABP).  
The role of PHLDA1 in tumors became the topic in recent time. There are few studies implying 
an oncogenic activity of PHLDA1
228-229
.  PHLDA1 is a putative epithelial stem cell marker in the 
human small and large intestine and contributes to migration and proliferation in colon cancer 
cells
230
. However, there is even more evidence that it acts as a tumor suppressor in certain tumor 
types
226, 231
. In human melanoma cells, when PHLDA1 is constitutively expressed it enhances the 
sensitivity to the chemotherapeutic agents doxorubicin and camptothecin
226
. In breast cancer 
PHLDA1 was shown to be a strong prognostic marker, where down regulation is being connected 
to poor survival
231-232
. PHLDA1 is crucial negative regulator of Aurora A kinase in breast cancer 
and at the same time is its substrate
233
. 
Previously we described PHLDA1 as a target gene of EWS/FLI1 in ES
234
. Through direct 
binding at the promoter of PHLDA1, EWS/FLI1 represses its expression. It is believed that 
through deregulated expression of many target genes EWS/FLI1 “drives” the fully malignant 
phenotype of ES cells
65, 99-102, 235
. Out of these target genes, quite many up-regulated target genes 
have been functionally characterized but only a hand full of directly repressed genes. Given the 
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fact that PHLDA1 is repressed in ES cells, we hypothesized that there must be some selective 
advantage for cancer cell and in that light PHLDA1 would probably have a tumor suppressor role 
rather than oncogene. Here we investigated the role of PHLDA1 in proliferation, apoptosis, cell 
detachment and cell adhesion in ES. 
Material and Methods 
Cell lines and plasmids 
RDES (type II fusion) cells were kindly provided by Prof. K.L.Schaefer (Institute of Pathology, 
Duesseldorf, Germany), A673 (type I fusion) cells were purchased from the American Type 
Culture Collection. Cells were cultivated on 0.1% gelatin-coated plates (Sigma-Aldrich, Buchs, 
Switzerland) in RPMI medium supplemented with 10% FCS, 1% penicillin/streptomycin and 1% 
L-glutamine, at 37
o
C in5% CO2. The PHLDA1b expression plasmids, GFP-PHLDA1b-pEGFP-
C1 and PHLDA1b-pcDNA3.1, were a gift of Prof. Dr. Richard Austin (Department of Pathology 
and Molecular Medicine, McMaster University and the Henderson Research Centre, Hamilton, 
Canada). Lipofectamine 2000 (Invitrogen) was used to transfect cells according to the 
manufacturer’s protocol. Cell lines with stabile over expression of PHLDA1 were crated upon 
selection with 800µg/ml G418 for 2 weeks. 
Adhesion assay  
96-well plates were coated with 15 µg/ml of fibronectin or laminin (Sigma-Aldrich, St. Luis, 
MO, USA) at room temperature for 1h. They were then washed with PBS and blocked with heat-
denatured 1% BSA (HD-BSA). Non-coated wells or wells coated with HD-BSA alone were used 
as controls. Adhesion assays were carried out with cells grown in tissue culture medium to 
subconfluency in 10cm Petri dishes. They were then detached with accutase (Sigma-Aldrich), 
resuspended in medium and seeded at 10
4
 cells per well and allowed to adhere at 37°C for 30 
minutes. Non-adherent cells were removed by washing with PBS and adherent cells were fixed 
with 10% formalin in PBS at room temperature (RT) for 15 minutes and then stained with 0.05% 
crystal violet in H2O at RT for 15 minutes. Images of randomly selected areas using 4x 
magnification. The number of adherent cells in the analyzed area was determined with ImageJ 
software (http://rsb.info.nih.gov/ij/ ). The total number of adherent cells per well was counted and 
the percentage of adherent cells was obtained by dividing the number of adherent cells by the 
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total number of seeded cells and multiplying with 100. The experiments were performed in 
triplicates and repeated three times. 
Proliferation assay and Caspase 3/7 assay 
About 5x10
3
 cells were plated in 96 well plate and growth was monitored by making 
measurements every 24h using WST-1 reagent (Roche) according to the manufacturer’s protocol. 
In the case of Caspase 3/7 activity, 2x10
4
 cells were plated in 96 well plate and 24h later cells 
were treated with either midostaurin (provided by Novartis), fenretinide (Sigma Aldrich) or 
DMSO. After 24h cells were lysed and assayed for Caspase 3/7 activity using CaspaseGlo kit 
(Promega) according to the vendor’s protocol.  
Human ES tissue microarray analysis  
ES tissue specimens were collected from 34 patients during primary tumor resection in 
accordance with the regulations of the local ethic committee. Clinical data of the patients are 
presented in Table 1. Microarray sections of 4.5 µm were processed as reported
236
 and stained 
with a monoclonal PHLDA1 antibody (Sigma Aldrich) (1:100) and counterstained with 
hematoxylin. Tissue microarray grading was performed based on the intensity. The intensity of 
the stain was judged by eye (negative, poor positive, moderate positive, strong positive).  
Results 
Based on the previous knowledge regarding the role of PHLDA1, especially implications of its 
putative tumor suppressor role in melanoma and breast cancer, we decided to perform a set of 
functional assays. For this reason we transfected two ES cell lines, namely A673 and RDES with 
PHLDA1 expression vector and under neomycin selection we established stabile cell lines 
(Figure 1).  
 
Figure 1 Protein expression of PHLDA1 in two ES stabile transfected cell lines 
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In order to check if there is any influence on the cell growth we plated these stabile cell lines and 
performed proliferation assay. As shown in the Figure 2 there was mild effect on cell 
proliferation. Despite the tendency towards slower growth in cells with over expression of 
PHLDA1 this effect was not significant.  
 
Figure 2 Proliferation of PHLDA1 over expressing ES cell lines: left panel proliferation of A673 cells, right panel 
proliferation of RDES cells; PHLDA1- stabile cell line overexpressing PHLDA1, NEO- stabile cell line transfected 
with empty vector, OD- optical density 
Given the fact that PHLDA1 was connected to higher levels of basal apoptosis in some human 
cells, we realized that the approach with stabile cell lines might not be the best, since it is 
possible that during the selection process we have selected for survivors and hence won’t be able 
to observe any influence on apoptosis. Therefore, we decided to work in parallel with cells 
transiently transfected with PHLDA1-GFP expressing vectors. In this way we would be able to 
monitor destiny of GFP positive cells in real time. Interestingly, already 24h after transfection 
with PHLDA1-GFP expression construct we observed distinct changes in cell morphology. These 
cells seamed more round, detaching from the plate and in total looked like they are undergoing 
apoptosis (Figure 3). At the same time, cells transfected with GFP as a negative control did not 
undergo any morphological changes.  
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Figure 3 A673 ES cells transiently transfected with GFP (A) or PHLDA1-GFP (B) expression vector 
This result led us to hypothesis that PHLDA1 might influence cell adhesion. To test this, we 
performed short term adhesion assay. Apart from testing adhesion to pre-coated plastic in tissue 
plates we also coated plates with laminin or fibronectin. As shown in Figure 4, there was a 
statistically significant reduction in adhesion of PHLDA1 overexpressing cells towards both fully 
coated plates as well as laminin only coated plates. This was not the case with adhesion to 
fibronectin. This confirms that PHLDA1 alters binding properties and adhesion of ES cells to 
extracellular matrix molecules and among these to laminin especially. 
 
Figure 4 Short term adhesion assay,  percentage of adhering A673 ES cells, PHLDA1- stabile cell line 
overexpressing PHLDA1, NEO- stabile cell line transfected with empty vector 
Since PHLDA1 has effect on adhesive properties of the cell we hypothesized that it might play a 
role in cell detachment mediated apoptosis. We performed caspase assay and measured caspase 3 
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and 7 activity in A673 cells transiently transfected with PHLDA1-GFP or GFP only expression 
vectors. As shown in Figure 5, after 48h as well as after 72h there was higher level of basal 
apoptosis in PHLDA1 over expressing cells. In melanoma cells was shown that higher levels of 
PHLDA1 expression are correlated to higher sensitivity to treatment with some 
chemotherapeutics.  Therefore, we treated these transiently transfected cells with PKC412 
(midostaurin), fenretinide or doxorubicin. We observed that PHLDA1 over expressing cells were 
more sensitive to PKC412 treatment than the negative cells (Figure 5), while this was not the case 
with either fenretinide or doxorubicin. Taken together these results imply that PHLDA1 
contributes to higher levels of basal apoptosis and at the same time renders cells more prone to 
midostaurin induced apoptosis.  
 
Figure 5 Caspase 3 and 7 activity (in relative luciferase units) of A673 ES cells transiently transfected with GFP or 
PHLDA1-GFP and treated with PBS, 500nM fenretinide, 500nM PKC412 or 500nM doxorubicine 
In the light of the effect of PHLDA1 on cell adhesion, it was interesting to identify a molecular 
connection. Furthermore, since there was pronounced effect of midostaurin, a broad spectrum 
kinase inhibitor, we wanted to elucidate connection of PHLDA1 and signaling molecules 
involved in these processes such as ERK signaling. When cells were stimulated with bFGF we 
observed an expected increase in phosphorylation of ERK (Figure 6). At the same time PHLDA1 
levels increased. Specificity of this effect was shown by using an inhibitor of FGF receptor, 
namely BGJ398. Along with pERK also PHLDA1 protein level went down upon use of the 
inhibitor. Thereby we confirmed direct influence of ERK on PHLDA1 levels. Furthermore, we 
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wanted to check if there is a negative feedback loop, where PHLDA1 would inhibit pERK. When 
cells were transfected with PHLDA1 expression vector and stimulated with bFGF, there was 
induction of phosphorylation of ERK but it was less prominent than in the case of non-transfected 
cells. Also, when cells were transfected with shRNA against PHLDA1, upon stimulation there 
was steady level of PHLDA1 and hence no negative feedback to pERK that was ultimately 
reflected by higher level of pERK. Taken together, these results suggest a link between ERK and 
PHLDA1. 
 
Figure 6 PHLDA1 and ERK signaling in A673 ES cells, (A) Scheme of feedback loop between ERK and PHLDA1, 
(B) western blot of pERK, total ERK, PHLDA1 and β tubulin as loading control; bFGF- basic fibroblast growth 
factor, BGJ398- inhibitor of FGF receptor (1- 500nM, 2- 1µM) 
Finally, we wanted to check the situation in tumor biopsies from patients. We performed 
immunohistochemical analysis of TMA containing samples acquired from 34 patients with ES 
(Table 1). This TMA was stained for PHLDA1 and based on the intensity of the staining, 
negative, poor positive, moderate positive and strong positive signals were distinguished.  
Table 1:  IHC analysis of PHLDA1 expression in Ewing sarcoma TMA 
 
+ poor positive, ++ moderate positive, +++ strong positive 
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As shown in Table 1, negative for PHLDA1 were 25, poor positive were 5, moderate positive 
were 4 and there were no strong positive samples. Week expression of PHLDA1 in tumor 
sections is therefore in complete accordance with the in vitro data
234
. Due to a small number of 
tumor samples it was not possible to draw any significant conclusions regarding progression free 
survival and overall survival. However, it is indicative that PHLDA1 positive tumors were less 
prone to metastasize (1 out of 9, 11%) in comparison to PHLDA1 negative ones (7 out of 25, 
28%). To obtain conclusive data it will be necessary to increase the number of tumor sections 
analyzed. 
Discussion 
Understanding ES is tightly related to understanding EWS/FLI1. Being a transcription factor that 
is crucial for both onset as well as maintenance of the tumor cell it is of outstanding interest to 
elucidate how is this regulated. It is believed that exactly through deregulated expression of 
numerous target genes EWS/FLI1 provides cell with the characteristic phenotype. Despite the 
efforts to pinpoint one or two target genes as the quintessential for ES it is now evident that much 
more target genes contributes in relatively small portions to what is known as ES. Therefore, 
starting on our previous discovery that PHLDA1 is repressed by EWS/FLI1 we decided to 
investigate the functional relevance of PHLDA1 in the context of ES.  
PHLDA1 has been shown to regulate apoptosis in vascular endothelial cells triggered by 
homocysteine
223
. PHLDA1 enhances cell death in neuronal cells, however without Fas 
induction
237
. Interestingly, PHLDA1 has already been implicated to play a tumor suppressor role 
in malignant melanomas where down regulation of PHLDA1 expression is associated with the 
progression of the desease
226
. In breast cancer was shown a direct correlation between amount of 
PHLDA1 and survival of the patients
231
. These discoveries suggested PHLDA1 as an interesting 
protein to investigate in cancer research. Having in mind the effect of PHLDA1 in breast cancer 
cell lines we focused on these very same cellular processes. ES cell lines stably transfected with 
PHLDA1 did not exhibit significantly impaired growth. However, upon transient transfection 
with PHLDA1 over expressing vector we observed morphological changes in ES cells, with 
characteristics of cell detachment induced apoptosis. Since it is known that proteins with 
plekstrin homology domain are involved in modulation of cellular morphology we assumed that 
PHLDA1 influences cell adhesion molecules. Therefore, we performed short time adhesion assay 
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showing that indeed PHLDA1 over expressing cells bind less to laminin while at the same time 
their binding to fibronectin is not affected. This suggests a possible connection between laminin-
binding integrins (α3β1, α6β1, α6β4, α7β1) and PHLDA1 expression. Since one of the major 
signaling pathways involved in the process of cell adhesion is ERK signaling we focused on 
finding a link between PHLDA1 and ERK. We were able to show the connection between 
activated ERK and PHLDA1 expression. Similarly, in breast cancer cells PHLDA1 was shown to 
be a negative regulator of ERK and opposes ERK-mediated transformation in breast epithelial 
cells
228
. 
Since higher levels of PHLDA1 in melanoma cells render them more sensitive to treatment with 
doxorubicin and camptothecin, we transiently overexpressed PHLDA1 in ES cells. These cells 
exhibited higher level of basal apoptosis but at the same time they were more sensitive to 
treatment with midostaurin and were not more sensitive to doxorubicin or fenretinide treatment. 
If we take into consideration that midostaurin, a broad spectrum kinase inhibitor, induces 
expression of PHLDA1
234
 we conclude that this effect together with overexpression of PHLDA1 
probably synergistically induces apoptosis. This fact might be useful for treatment, since only 
PHLDA1 positive tumors should be sensitive. 
Apart from the extensive in vitro data it was interesting to analyze the situation in tumor biopsies. 
Hence, we performed staining TMA sections for PHLDA1 expression and subsequent analysis. 
Despite the fact that we had very small number of tumors in TMA, only 34, the result was 
corroborating previous finding that PHLDA1 is weakly expressed in vast majority of tumors. Too 
small sample size did not allow to correlate PHLDA1 expression and patient survival. However, 
it is quite interesting that PHLDA1 expressing tumors metastasized nearly 3 times less than non-
expressing ones, consistent with a tumor suppressive role of PHLDA1. 
Taken together, these results imply that PHLDA1 as a direct target of EWS/FLI1 has a role in 
apoptosis, cell detachment and cell adhesion of ES cells. Considering also the indicative TMA 
results it is tempting to speculate that PHLDA1 has tumor suppressor function in ES. Further 
studies should substantiate these findings.  
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Ewing sarcoma (ES) is the second most frequent bone cancer in childhood. Clinically, ES 
appears as very aggressive osteolytic tumor with early tendency for development of metastasis. It 
belongs to the group of small-round-blue-cell tumors and is comprised of largely undifferentiated 
cells. The unique feature of this tumor is presence of the balanced t(11;22)(q24;q12) translocation 
in more than 85% of cases
44
. This gene rearrangement results in the expression of a chimeric 
fusion protein where RNA binding domain of EWS is exchanged by the DNA binding domain of 
the ets transcription factor FLI1, thus generating a dysregulated transcription factor EWS/FLI1
45
. 
Extensive evidence indicates that EWS/FLI1 is a hallmark of ES development.  Its oncogenic 
activity is thought to be mediated through inappropriate regulation of target genes that are crucial 
for the fully malignant phenotype
65, 99-102, 235
. Considering this, identification of target genes 
regulated by EWS/FLI1 protein represents an important step in understanding the underlying 
molecular mechanisms. Therefore, identification and characterization of novel EWS/FLI1 target 
genes was one of the aims of this thesis. Hence, we combined microarray analysis of patient 
tumor biopsies with cell line tumor models to define new EWS/FLI1 target genes. This resulted 
in a list of six genes that are candidate targets of the fusion protein. The only gene in this list 
whose expression is low in ES patient tumors compared to other small blue cell tumors and is 
induced upon silencing of EWS/FLI1 was PHLDA1, suggesting that PHLDA1 is repressed by the 
fusion protein. Additional examination of more recently published microarray data revealed 
PHLDA1 as top-ranking gene in two different studies as well 
103-104
 thus confirming our analysis. 
To confirm that PHLDA1 is indeed a EWS/FLI1 target gene we performed detailed analysis of its 
promoter. Therefore, we performed a series of luciferase assays with various deletion and point 
mutation constructs of the PHLDA1 promoter. These experiments indicated that EWS/FLI1 
represses expression of PHLDA1. Finally, chromatin immunoprecipitation experiment confirmed 
direct binding of EWS/FLI1 to the promoter of PHLDA1. Knowing that PHLDA1 is repressed by 
EWS/FLI1 we decided to investigate the functional relevance of PHLDA1 in the context of ES.  
PHLDA1 has already been implicated to be a tumor suppressor in malignant melanomas where 
down regulation of PHLDA1 expression is associated with the progression of the desease
226
. The 
amount of PHLDA1 was shown to be in a direct correlation with a survival of the patients
231
. All 
this led us to hypothesis that PHLDA1 might have similar tumor suppressive role in ES as it has 
in melanoma and breast cancer. Even though ES cell lines stably transfected with PHLDA1 did 
not exhibit significantly impaired growth we observed morphological changes upon transient 
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transfection with PHLDA1. These cells displayed characteristics of cell detachment induced 
apoptosis. Since it is known that proteins with plekstrin homology domain are involved in 
modulation of cellular morphology we hypothesized potential link between PHLDA1 expression 
levels and integrins and/or other cell membrane molecules in charge for binding to extracellular 
matrix. To test that we performed short time adhesion assay showing that indeed PHLDA1 over 
expressing cells bind less to laminin and at the same time their binding to fibronectin is not 
affected.  
Melanoma cells show sensitivity to treatment with doxorubicin and camptothecin that is in direct 
correlation with PHLDA1 levels. In ES cells overexpression of PHLDA1 led to increase in level 
of basal apoptosis. At the same time these cells were more sensitive to treatment with 
midostaurin. Considering that midostaurin is inducing expression of PHLDA1
234
 it is possible 
that PHLDA1 overexpression and midostaurin act synergistically on apoptosis. Knowing this we 
assume that PHLDA1 positive tumors would be more sensitive to treatment and this might be 
useful for the treatment with midostaurin. 
Finally, we performed staining TMA sections for PHLDA1 expression and subsequent analysis. 
Despite the fact that we had very small number of tumors in TMA, only 34, the result was 
confirming previous finding that PHLDA1 is highly repressed in vast majority of tumors. 
However, small sample size did not allow us to make correlation of PHLDA1 expression and 
patient survival. Nevertheless, it is interesting that PHLDA1 expressing tumors metastasized 
nearly 3 times less than non-expressing ones.  
These results imply that PHLDA1 is important target gene of EWS/FLI1 since it plays a role in 
apoptosis, cell detachment and cell adhesion of ES cells. In vitro data together with TMA results 
suggests that PHLDA1 has tumor suppressor function in ES.  
Pediatric sarcomas are rare and this is the main obstacle for development of novel therapeutic 
approaches. Even though that expression of oncogenic fusion proteins generated by distinct 
chromosomal translocations is necessary for both tumor development as well as tumor 
maintenance, direct targeting of these transcription factors using small molecules is still not 
possible. Therefore, in this thesis we decided to address this issue. 
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We established an expression based read-out system to measure modulation of transcriptional 
activity of EWS/FLI1 for small molecule discovery. Based on measuring expression levels of 
only few direct target genes, this approach was an important simplification of the previously 
applied gene expression based high-throughput screening 
177
. At the same time this is more 
targeted approach than screenings based on survival or proliferation only, while it is more robust 
than a screening approach based on a single-gene reporter assay 
238
. To increase the robustness of 
our approach, we quantitatively measured expression of both activated as well as repressed target 
genes of EWS/FLI1 since we expected that unspecific killing would result in generally reduced 
mRNA levels. 
From the 1280 compounds screened with the small molecule library, we identified among the top 
10 hits well known chemotherapeutic agents such as camptothecin, etoposide, idarubicin and 
doxorubicin. In this list was also fenretinide which is undergoing clinical trials for neuroblastoma 
and ES 
239-240
. Interestingly, in recently published work of Barretina et al, ES cell lines were most 
sensitive to topoisomerase I inhibitors (derivatives of captothecin) among the panel of 479 
different cell lines thus confirming results of our screening
241
. Altogether, these results emphasize 
the robustness of our screening approach and suggest that it can be expanded to additional 
compound and/or targeted inhibitor libraries.  
One of the most promising novel compounds identified in our screen was the pan-kinase inhibitor 
Midostaurin. This is a small-molecule kinase inhibitor derived from Staurosporine that inhibits 
several kinases
242-243
. Midostaurin is currently undergoing phase II clinical trials for treatment of 
leukaemias in adults and in children. As the population of patients available for phase I and II 
clinical trials with pediatric solid tumors is very limited, midostaurin represents a small molecule 
with already established low toxicity for such trials. In addition, midostaurin was already shown 
to be effective against another childhood sarcoma, rhabdomyosarcoma 
244
. Hence, we further 
evaluated its effect against a large panel of ES cell lines which responded to midostaurin 
treatment at the high nM range with massive apoptosis similar to etoposide that is currently used 
in ES therapy.  
Midostaurin is able to reduce cell growth, induce apoptosis and reduce tumor growth in vivo. 
Similarly to rhabdomyosarcoma, ES xenografts showed high sensitivity upon treatment with the 
kinase inhibitor midostaurin. In rhabdomyosarcoma, midostaurin modulates phosphorylation 
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status of the translocation PAX3/FKHR thus inhibiting its transcriptional activity 
245
. Based on 
this we might conclude that pan-kinase inhibitors could have a therapeutic potential in ES and 
maybe even sarcomas in general. Therefore, they should be considered for the future treatment of 
such childhood tumors. 
Complexity of ES is not caused by a single driving event and therefore it is necessary to elucidate 
all the major contributors to the fully malignant phenotype. Therefore, we had an aim to use our 
well established screening approach, only this time to screen a small library of targeted inhibitors 
that are inhibiting different signaling pathways in order to identify critical pathways. As the most 
prominent pathway that regulates EWS/FLI1 activity/expression we identified the PI3K pathway. 
This confirmed earlier findings demonstrating that IGF1R signaling via PI3K is a very important 
axis in ES cells
136, 183-184, 187
. Indeed, in a subgroup of patients inhibition of IGF1R using 
monoclonal antibodies showed good initial response. IGF1R leads to activation of several 
signaling pathways, whereas MAPK pathway is crucial for cell proliferation and PI3K pathway 
for anti-apoptotic effect
246
. There was an improved therapeutic response when anti IGF1R 
antibodies were combined with PI3K/mTOR inhibitors. However, even with such combined 
therapy in some patients resistance was observed. This implies that some other signaling 
pathways are taking over and provide cancer cell survival. 
The most potent compound in our hit list was BEZ235, a dual PI3K and mTOR inhibitor. This 
compound induced a strong decrease of EWS/FLI1 on both RNA and protein level. Surprisingly, 
very little is known about the regulation of EWS/FLI1 expression and there is only one available 
study suggesting possible regulatory transcription factors
247
.  Previously was shown that 
inhibition of mTOR by rapamycin decreases EWS/FLI1 protein levels
220
. Therefore, we validated 
BEZ235 and demonstrated that the effect on the EWS/FLI1 expression is specific. Moreover, by 
performing a series of luciferase experiments with the EWS/FLI1 promoter we showed for the 
first time the direct control of EWS/FLI1 promoter and thus its expression by the PI3K pathway. 
In a series of reporter gene assays we were able to determine the exact regulatory element within 
the promoter. However, to determine the identity of the transcription factor(s) under PI3K control 
that is binding in this region additional studies are necessary. Computational analysis of the 
sequence suggests several potential binding factors, some of them known to be controlled by the 
PI3K pathway. One of the candidates is NF-κB, transcription factor well known to be controlled 
by PI3K signaling. Future experiments will elucidate this issue. 
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Despite the fact that targeting IGF1R/PI3K signaling shows good results in ES
181, 196, 202-203
, the 
mechanism responsible for the efficacy of anti-IGF1R therapy is still not clear. Silencing 
EWS/FLI1 has stronger pro apoptotic effect than IGF1R antibody which suggests there is a need 
for more direct targeting of EWS/FLI1 
248
. It is possible that IGFBP3 as target of EWS/FLI1 can 
induce apoptosis independently of IGF system
103
. Also, some of other EWS/FLI1 target genes 
might contribute to induction of apoptosis upon silencing EWS/FLI1. Therefore, apoptosis 
induced by BEZ235 or other IGF1R/PI3K inhibitors might be a result of decrease in EWS/FLI1 
expression. Hence, revealing the direct link between PI3K and EWS/FLI1 is of importance, and 
identity of the responsible transcription factor(s) might provide novel therapeutic opportunities. 
The work performed in this thesis opened up several possibilities as future challenges. Our 
screening of targeted inhibitors pointed out which signaling pathways are important for the 
biology of ES. We focused on PI3K pathway as the most prominent candidate in our screening. 
However, there are other pathways whose inhibition resulted in very specific gene expression 
signature. Moreover, some of these pathways have never before been described in context of ES 
and it would be interesting to investigate their role in more depth. Given the fact that single 
pathway inhibition is often not enough due to the cross-talk between pathways and other 
resistance mechanisms, the future approach might be to simultaneously target two signaling 
pathways at the same time and thus ensure successful tumor cell targeting. Also, combining hit 
compounds from our first screening with targeted inhibitors might be an interesting approach. 
Even though the mechanism of action is not known for some compounds, this should not prevent 
us from using those compounds. Camptothecin was the top compound in the first screening and 
its derivative irinothecan is already in clinical trials for treatment of ES. On the other hand 
BEZ235 is also in clinical trials as single agent. Since both of these mechanistically very different 
compounds have been shown to reduce EWS/FLI1 levels in this work, it is reasonable to assume 
that combined use of these two would have synergistic effect that would lead to reduced dosage 
and hence lower side effects.  
In majority of cancer types oncogenic phenotype is driven by transcription factors which 
therefore represent prime therapeutic targets. However, direct targeting of transcription factors is 
not easy since they usually do not have enzymatic activity. So far, only handful of transcription 
factors has been successfully targeted by direct inhibition. Recent example is inhibition of GLI 
with antagonist GANT61 that leads to reduced expression of its target genes and preferentially 
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decreased viability of malignant cells in CLL through induction of apoptosis
249
. In sarcomas and 
leukemias often cancer cell specific gene rearrangements are present that lead to expression of 
fusion transcription factors. In this case fusion proteins are frequently crucial drivers of the fully 
malignant phenotype. Moreover, being expressed exclusively in cancer cells makes them even 
more appealing therapeutic targets since they provide necessary distinction from normal cells. 
Therefore, many research groups focused on inhibition of protein interactors, since these fusion 
transcription factors cooperate with other proteins in assembling the final transcription complex 
on DNA. One successful case of such targeting was demonstrated in MLL-fusion leukemias. 
Since MLL-fusion proteins are associated with BET family of acetyl-lysine recognizing, 
chromatin adaptor proteins, it was shown that small molecule inhibitor I-BET51 prevents binding 
of Bnd3/4 adaptor protein to chromatin thus abolishing activity of MLL-AF4 or MLL-AF9 fusion 
transcription factor
250
. 
The presence of fusion transcription factors in many cancers, such as synovial sarcoma, myxoid 
liposarcoma and rhabdomyosarcoma makes this field even more attractive since a successful 
targeting strategy in one fusion protein driven tumor type might be extrapolated to the other 
similar tumor types. Targeted inhibitor of one fusion transcription factor might be effective 
against other similar fusion transcription factors. This was nicely demonstrated for ET-743, an 
inhibitor of FUS/CHOP transcription factor in myxoid liposarcoma that was shown to be 
effective against EWS/FLI1 activity in ES
251
. The screening approach established in this thesis in 
essence provides proof of principle and thus it might be used in other similar cancers. The 
advantage of our approach is that it can be used to discover modulators of fusion transcription 
factor activity/expression irrespective of the mechanism of action. This is very important as it 
seems extremely difficult to find direct inhibitors. Moreover, screening approach here described 
might lead to increased knowledge about signaling pathways that are of importance for ES 
biology and finally to discovery of novel therapeutic targets. 
In conclusion, the results presented in this thesis demonstrate that our screening approach can be 
used for both screening for compounds effective against ES as well as for screening targeted 
inhibitors. Together this should help to develop novel therapeutic approaches for the treatment of 
ES. 
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